International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

Vol. 41 No. 1 October 2023, pp. 387-416

Immuno-Oncology In Cancer Cervix Treatments

Literature Review

Maged Naser[1], Mohamed M. Nasr[2], and Lamia H. Shehata[3]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,

[2]King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,

[3]Care National Hospital, Department of Radiology

Abstract – It is an unhappy truth that regardless of being almost fully preventable through human papillomavirus (HPV) vaccination and screening, cervical cancers remains the fourth most common cancers to have an effect on women. High risk HPV infection (hrHPV) is the number one etiological element for cervical cancer. Upto 70% of instances are via HPV types 16 and 18, with many different hrHPV related to the rest of cases. Modern-day trendy- of- care treatments consist of radiotherapy, chemotherapy, and/ or surgical resection. still, they have got good sized side effects and limited efficacy against advanced disease. there are few treatment choices for recurrent or metastatic cases. Immunotherapy gives new stopgap, as demonstrated with the aid of the current blessing of PD1 blocking antibody for recurrent or metastatic disease. This might be augmented by way of mixture with antigen-specific immunotherapy tactics, comparable as vaccines or adoptive cellular transfer, to enhance the host cell immune response targeting HPV-positive cancer cells. As cervical cancers progresses, it is able to foster an immunosuppressive medium and counteract host anticancer immunity. therefore, procedures to reverse suppressive susceptible surroundings and bolster effector T cellular functioning are probable to enhance the success of comparable cervical cancers immunotherapy. The success of non-specific immunostimulants like imiquimod against genital warts additionally propose the possibility of exercising those immunotherapeutic strategies in cervical cancer prevention to deal with precursor lesions(cervical intraepithelial neoplasia) and affected person hrHPV infections against which the licensed prophylactic HPV vaccines haven't any efficacy. We assessed the progress and demanding situations inside the development of immunotherapeutic processes for the prevention and treatment of cervical cancer.

Keywords – Human Papillomavirus; Cervical Cancer; CIN2/3; Immunotherapy.

I. INTRODUCTION

Cervical cancer is the fourth most common female cancer worldwide(1,2) and one of the pinnacle three cancers to have an effect on women younger than forty five(3). Globally there had been more or less 570,000 cases of cervical cancers and 311,000 deaths in 2018, demonstrating the extensive worldwide burden of the cancers(3). For countries with an excessive Human improvement Index (HDI), cervical cancers has a 5- year survival rate of 60 – 70%, whereas in nations with low HDIs it falls to < 20 (2,4). within america, survival has not substantially bettered for cervical cancer cases since the 1970s (5) demonstrating the critical need to improve on current treatment strategies for cervical cancers. The precursors of cervical cancers are categorized into grades of including inflexibility of dysplasia Cervical Intraepithelial Neoplasia grades 1, 2, and 3 (CIN1, CIN2, and CIN3, respectively). CIN1, additionally referred to as low- grade squamous intraepithelial lesions(LSIL), represents an effective HPV infection, at the same time as CIN2/3, also referred to as high- grade squamous intraepithelial lesions(HSIL), and are taken into consideration to be the instantaneous precursor lesion. CIN1 lesions constantly spontaneously regress by virtue of immune system clearance after HPV infection. nevertheless, CIN2/3 is related to lower rates of retrogression. individualities with CIN2/ 3 are at a high risk for growing cervical cancer if left untreated via ablation by means of conization / LEEP(6).

Corresponding Author: Maged Naser

For instances with recurrent or metastatic cervical cancer (r/ mCC) who can not admit restorative motive surgical procedure or radiotherapy, platinum based chemotherapy with bevacizumab, if now not contraindicated, is wellknown(7,8). This authority provides a mean normal survival(zilches) of14.3 –18.3 months(9,10), and, until currently, there has been little advantage with alternate- line systemic curatives. instances with LACC handled with curative intent have a higher prognostic than those with r/ mCC. Chemoradiotherapy(CRT) got here the slandered care of LACC in 1999, furnishing enormous enhancement in disease-free survival(FS) and zilches over radiotherapy on my own(11); intracavitary brachytherapy following CRT in addition bettered problems and is taken into consideration an imperative detail of CRT(4,12). notwithstanding definitive CRT, cases with LACC revel in 5- time DFS and OS of 47 – 80%(13 –15), with poorer survival for degree IIIB/ IVA or with nodal involvement(15,16). latest tries to enhance CRT have persisted reversal; addition of adjuvant chemotherapy to CRT didn't ameliorate survival inside the segment III OUTBACK trial(17). Immunotherapy is a promising arising choice supported through more than one findings. First, almost all cases of cervical cancers stand up after patient persistent infection with a high risk HPV subtype(18). Integration of HPV E6 and E7 viral oncoproteins into the cell genome permits for their restrained expression, developing a conducive enviroment for further inheritable mutations associated with tumor cellular survival and immune escape(19). This immune system supression is a crucial step in development of cervical cancers. Second, programmed cellular loss of death ligand- 1(PDL1) is notably expressed inside the tumor microenviroment(20). Third, the presence or absence of tumor- infiltrating immune cells has prognostic importance in cervical cancer(21). in the end, with admire to treatment for LACC, radiotherapy will increase antigen generation and presentation, T- cell priming, dendritic activation, as well as situations of proinflammatory cytokines(22), and small clinical trials of radiotherapy based remedy mixed with immunotherapy display pledge(23,24). Immunotherapies that at once target cervical most cancers and provide ingrain antitumour items in addition to those who serve to extinguish the vulnerable machine towards cervical excrescences are below disquisition. In June 2018, pembrolizumab was once the primary immunotherapy to admit US food and Drug management(FDA) increased blessing as trade- line remedy for cases with PD- L1-fine affected person or r/ mCC. In 2021, 2 clean FDA benefits have been granted tisotumab vedotin for change- line r/ mCC and pembrolizumab combined with chemotherapy ± bevacizumab for first- line PD- L1-superb patient or r/ mCC. With at least two dozen clean immunotherapies in medical trials (25 – 33), the remedy geography for cervical cancer is on the verge of a paradigm shift. more than one composites are in colourful tiers of improvement that examine the eventuality for enhancement in efficacy and protection in different treatment traces and cervical most cancers levels. With numerous of those in early ranges, precise blessings and pitfalls for those redress remain to be visible. Then we evaluate fundamental trials of immunotherapies that had been currently permitted or have the eventuality for non-supervisory consideration through 2024 (33) and bandy biomarkers and histologic kind in terms of immunotherapy, in addition to expected demanding situations.



Fig. 1. FIGO 2018 staging system for cervical cancer. *Early-stage cervical cancer includes stage IA1-IB2 and IIA1, and locally advanced disease includes stages IB3 and IIA2–IVA. Adapted from Table 1 in Bhatla et al, 2018 [34].

Conization and LEEP are associated with hazard of recurrence, cervical incompetance and premature delivery of future pregnancies and related risks to the child , so an immunotherapeutic treatment modality could be a complementary method or certainly an alternative. Remedy methods and outcomes for cervical cancer cases are largely depending on disease stage at diagnosis (35,36), with 5 year survival starting from over 90% if recognized in an early, localized stage to less than 20% if identified as distant or metastatic(36). Remedy options for early- stage and locally invasive cervical cancer encompass radical hysterectomy or radical trachelectomy with pelvic lymphadenectomy and concurrent chemotherapy and radiation treatment. For distant metastatic cervical most cancers, the remedy makes a speciality of systemic therapies(35,37– 40)). With the low therapy rates for advanced disease and side effects of current curatives, new remedial alternatives for cervical cancers cases are desperately demanded. Immunotherapy is an anti- cancers approach that goals to alter and recruit the host immune system to greater correctly and in particular goal most cancers cells; it is a developing subject that offers hope for bettered cervical cancer treatment and survival. currently, using immunotherapy for the treatment of cervical cancers and survival, although solely one

immunotherapeutic medicine(pembrolizumab) has to this point been approved via the FDA for use against cervical cancers. Hman Papillomavirus(HPV) is a critical but no longer enough etiological component of cervical cancer. HPV is a common sexually transmitted infection, but most HPV infections are cleared through the body's immune system. whilst these genital mucosal hrHPV infections persist they drive cellular proliferation and genomic instability and finally progression to malignancy if unchecked. HrHPV infection therefore produces high grade CIN(aka scaled intraepithelial lesions(SIL)), which constitute the precursor lesion of cervical cancer(41). The remainder of the >200 known HPV genotypes don't cause cancer and are considered low risk (42). HPV are also classified by their tropism toward mucosal and cutaneous epithelia and those low risk HPVs cause benign genital and skin warts. HPV found in more than 95% of all cervical cancers(1,43), with high risk types being related to over 85% of cervical cancers cases, and mainly HPV16 and HPV18 are the most commonplace excessive- risk types(44). likewise, hrHPVs are also answerable for the malignant transformation of other mucosa and were related to penile, vaginal, vulvar, anal, and head and neck(oropharyngeal) cancers, even though HPV16 is by way of a ways the dominant kind(44 – 49). HPV is a small (8000 base pair), non-enveloped, double-stranded, oblique DNA virus(50) . The HPV genome expresses an early transcriptional program encoding E1, E2, E4, E5, E6, and E7, which alter the viral life cycle, and late transcriptional encoding proteins, major and minor capsid proteins L1 and L2, that are structural elements for genome encapsidation and virion assembly. while E1 is a replication factor, E2 is a transcreption of all HPV viral proteins, in a position of regulating viral DNA replication and viral RNA transcreption. E4 regulates the cytoskeleton form of infected epithelial cells to promote virion release. E5, E6, and E7 interfere cell transformation. E6 and E7 are especially essential, as they are oncoproteins that repress tumor suppressors p53 and pRb, respectively. They disrupt the activation of apoptotic pathways and promote cell proliferation, subsequently leading to the development of HPV-related malignancies(45,47).

Throughout cancer development, viral integration into the host genome regularly results in the lack of E2, E4, E5, L1, and L2 expression, whereas local expression of E6 and E7 oncogenes is necessary for cancer cell survival and growth. identifying hrHPV as the primary and crucial etiological thing of cervical cancers and other HPV- related cancerous malignancies has been central to the development of immunization strategies to prevent its associated cancers. There are precautionary vaccines that set off neutralizing antibodies towards HPV and establish protective impunity using L1 virus like particles(51). Commercially available precautionary vaccines encompass the bivalent Cervarix ®(GlaxoSmithKline) andmulti-valent Gardasil ® and Gardasil- 9 ®(Merck)(52 – 54). Gardasil- nine ® has multiplied content to HPV kinds 6, 11, 16, 18, 31, 33, 45, 52, and 58(52,55) and is the dominant vaccine inside the united states. these vaccines cover naive individualities from constricting HPV infections centered by the vaccine;(56,57) nevertheless, these preventative vaccines haven't been successful in treating set up HPV infections(58). unluckily, precautionary HPV vaccination quotes were low globally, in particular in low- income nations(59). In 2016, solely 50% of women aged13 – 17, the target demographic for the vaccine, have been vaccinated with an HPV vaccine in the USA(5), and vaccination rates can range appreciably globally and between ethnical groups(60). Barriers to starting and finishing the full precautionary vaccine series encompass maternal attitude, race/ethnecity, cultural, beleifs regarding sexual activity, insurance status, geographic position, socioeconomic status, low information amongst healthcare carriers. (60–62)

Furthermore, given the pretty contemporary introduction of HPV vaccination, however, in 2018 the FDA accepted of raising the age cap for Gardasil-9 management from 26 to 45 for men and women (63). however, ordinary low prophylactic vaccination rates amongst teens and pre-existing infections in older women demonstrates the urgent need for the development of therapeutic HPV vaccines to cope with HPV-associated cervical dysplasia and cervical cancer. because of their role in most of the people of cervical cancers cases, high risk types HPV16 and HPV18 had been the foremost focal factor for growing HPV antigen specific immunotherapies (64). infected basal epithelial cells that harbor the virus completely categorical the early genes. while HPV integrates into the host genome at some stage in progression, normally, the oncogenic E6 and E7 genes are integrated and expressed whereas the distinctive HPV genes are out of place or not expressed (65,66). As a result, neutralizing antibodies (and L1-specific T cells) generated via prophylactic vaccines are not effective in against those HPV-infected cells. In a try to clear HPV infections or pre-existing HPV-related lesions, therapeutic HPV vaccines are being developed.

Therapeutic vaccines generate T cell-mediated immunity via using especially targeting HPV early antigens which might be constitutively expressed throughout each infected and cancerous cells (67,68). in particular, the E6 and E7 proteins characterize two logical therapeutic HPV vaccine targets because they are constantly expressed and required to hold malignant transformation of HPV-associated cancers (66,69). for that reason, most immunotherapeutic HPV strategies center of interest on producing and enhancing T cells specific for the HPV E6 and E7 antigens, however distinct viral antigens can probably be centered while

treating precursor lesions or infection (e.g. E1 and E2). every other vital immunotherapeutic approach is adoptive cell therapy (ACT). This technique is commonly personalised to the affected person, and involves removing naturally occurring tumor-reactive and targeted lymphocytes (tumor-infiltrating lymphocytes, TIL), increasing these with or engineering desired phenotypes in vitro, then re-administering the lymphocytes in significantly more quantity (70,71). even though the efficacy of ACT has typically been confined in competition to solid tumors (72), there are ongoing research that practice this approach to cervical cancers. For cervical cancers TILs are generally selected for HPV E6 and E7 reactivity, though contemporary proof propose that the cancers additionally include extra neoepitopes that can be focused (73). As cervical cancers cells proceed to stay clear of immune surveillance, many immunosuppressive factors are upregulated in the TME. Immune get away is associated with each downregulation of the immune system locally and evasion of detection, together with an enlarge in regulatory T cells (Tregs), loss of major histocompatibility complex (MHC) antigen presentation, chronic inflammation, and upregulated immune checkpoint molecules (74). consequently, beyond centered on tumor antigen, a primary immunotherapeutic method is to reverse immunosuppression or effector T cellular cell suppression. those techniques are no longer HPV antigen specific and if successful, they can be tremendous in cervical cancers regardless of HPV type or association. for example, immune checkpoint blockade targets cell sudface checkpoint molecules such as PD-1/PD-L1 and CTLA-4 with antibodies (75). The upregulation of immune checkpoint molecules in the TME is a part in cancers immune escape as increased PD-1/PD-L1 activity downregulates T cell function. consequently, by blocking of immune checkpoint function, T cells will continue to proliferate in the TME and clear cancers cells. In 2018, the FDA approved pembrolizumab for PD-L1 effective metastatic or recurrent cervical cancers. even as pembrolizumab has a response rate for these patients of total ~15% (76) this represents an integral first step. In all, immunotherapy is a promising approach for cervical cancer, specially as it provides unique, non-viral antigen targets. by virtue of the near ubiquity of HPV in cervical cancers, antigen unique treatments focused on hrHPV oncoproteins can prime the host immune system to aim HPV-expressing cancers cells. Secondly, as cervical cancers progresses, alters the TME, and suppresses the immune system, strategies to assist effector immune cells and opposite immune suppression still attractive. modern-day preferred-of-care for cervical cancers patients is woefully insufficient, as there's a lack of cure options, low survival rate for metastatic/recurrent patients, and massive side effects. when in comparison to exclusive gynecological cancers such as ovarian or endometrial, cervical cancers patients will be predisposed to be younger and feature fewer treatment options. developing novel, specifically awesome immunotherapeutic techniques, both independently or in combination with trendy-of-care or one of a kind immunotherapies, is consequently of excellent medical interest to enhance results for these patients.

II. Strategies to Generate Cervical Cancer Specific T Cells

A plethora of vaccine techniques are being tested for cervical cancer immunotherapy, a lot of which aim HPV early proteins, predominantly E6 and/or E7. Vaccine sorts consist of live vector, protein/peptide, nucleic acid, and cell based vaccines. those antigen-specific forms of immunotherapy stimulate antigen presentation by MHC type I and II, which ends up in the generation of CD8+ cytotoxic and CD4+ helper T cellular responses. A fundamental attention with therapeutic vaccines is their reliance on an intact immune system, which might be no longer easy in patients with immunosuppression (organ transplant recipients, or HIV+ patients) who are at multiplied chance for HPV-related cancers.

Live vector-based vaccines use either bacterial or viral vectors, counting on the chosen platform. they could induce strong cellular and humoral immune responses, possibly with a single dose (58). however, live-vector primarily based vaccines can pose as a safety risk, especially in immunocompromised patients, and immunity to the vector can dominate and/or stop boosting with the same vector. several HPV therapeutic vaccine candidates have bacterial vector bases, including Listeria monocytogenes, Lactococcus lactis, Lactobacillus plantarum, and Lactobacillus casei (77– 80). Listeria is a specially promising vector owing to its capability to infect macrophages and secrete listeriolysin O (LLO), a pore-forming toxin to interrupt out phagosomal lysis, permitting it to duplicate in the cytoplasm of the host cell (81). the cytoplasm and endosomal compartments, antigen peptides may be delivered via MHC type I and MHC type II with a view to recruit both cytotoxic and helper T cells (82). Listeria based vaccines carrying E7 antigen have been tested to elicit awesome immune reaction towards E6/E7-expressing tumors (77,83). Listeria vaccines for the treatment of cervical cancer are clinically encouraging. ADXS11–001 vaccine, a Listeria-primarily based bacterial vector vaccine encoding HPV16 E7, has proven promise for patients with recurrent or persistent cervical cancer (84). live viral vector vaccines express target antigens by the use of infecting cells and hijacking translation machinery. a couple of viral vector vaccines were advanced to purpose E6 and E7 antigens, which consist of adenoviruses, adeno-associated viruses, alpha viruses, and vaccinia viruses (85– 88). Vaccinia is at present amongst the maximum promising, due to its immoderate infectivity,

safety record, and low risk of integration into host DNA genome (89). Vaccinia-based vaccines include encoding the vector with E7 fused to calreticulin, E7 fused to LLO, and SigE7 LAMP-1, in which E7 is related to sorting signals and a lysosomal-related membrane protein (88,90). Human Antigen-Human Papillomavirus (TALLY-HO) is a vaccinia-live vector vaccine that encodes mutated E6 and E7 oncoproteins for HPV16 and HPV18. Early medical trials with TALLY-HO mounted its potential to result in HPV-particular cytotoxic T-cell responses in patients with cervical cancer (89) and patients with HPV-associated high-grade vulvar intraepithelial neoplasia (VIN III) and high-grade vaginal intraepithelial neoplasia grade two (VAIN II) (91). Additionally, Tipapkinogen Sovacivec (TS) vaccine makes use of a Modified Vaccinia virus Ankara (MVA) vector encoded with genes for HPV16E6/E7 and IL-2 (92). As there may be a loss of therapy selections, low survival cost for metastatic/recurrent patients, and massive aspect outcomes. whilst in distinction to top notch gynecological cancers which encompass ovarian or endometrial, cervical cancers patients will be predisposed to be youthful and have fewer treatment selections. developing novel, highly effective immunotherapeutic strategies, either independently or in combination with standard-of-care or first-rate immunotherapies, is consequently of magnificent scientific interest to improve consequences for these patients.

1. Methods to Generate and Enhance Cervical Cancer Specific T Cells

A plethora of vaccine techniques are being examined for cervical most cancers immunotherapy, plenty of which target HPV early proteins, predominantly E6 and/or E7. Vaccine kinds consist of live vector, protein/peptide, nucleic acid, and cell based vaccines. these antigen-specific kinds of immunotherapy aim to stimulate antigen presentation with the aid of MHC type I and II, which consequences in the generation of CD8+ cytotoxic and CD4+ helper T cellular cell responses. A quint essential interest with therapeutic vaccines is their reliance on an intact immune system, which is probably no longer convenient in patients with immunosuppression (organ transplant recipients, or HIV+ patients as an example) who are at extended risk for HPV-related cancers.

1.1 Vaccine Strategies

1.1.1 Live Vector Based Vaccines

Live vector-based vaccines use both bacterial or viral vectors, relying on the selected platform. they can start off strong cellular and humoral immune responses, probably with a single dose (58). however, live-vector based vaccines can pose as a protection hazard, in particular in immunocompromised patients, and immunity to the vector can dominate and/or forestall boosting with the identical vector. numerous HPV therapeutic vaccine candidates have bacterial vector bases, including Listeria monocytogenes, Lactococcus lactis, Lactobacillus plantarum, and Lactobacillus casei (77– 80). Listeria is a specially promising vector by virtue of its ability to infect macrophages and secrete listeriolysin O (LLO), a pore-forming toxin to escape phagosomal lysis, enabling it to copy within the cytoplasm of the host cell (81). the cytoplasm and endosomal compartments, antigen peptides may be delivered with the aid of way of MHC type I and MHC kind II so that it will recruit both cytotoxic and helper T cells (82). Listeria based totally vaccines wearing E7 antigen were tested to elicit considerable immune reaction in opposition to E6/E7-expressing tumors (77,83). Listeria vaccines for the therapy of cervical cancers are clinically encouraging. ADXS11–001 vaccine, a Listeria-based bacterial vector vaccine encoding HPV16 E7, has established promise for patients with recurrent or persistent cervical cancers (84). live viral vector vaccines categorical purpose antigens by way of infecting cells and hijacking translation machinery. a couple of viral vector vaccines had been evolved to goal E6 and E7 antigens, inclusive of adenoviruses, adeno-related viruses, alpha viruses, and vaccinia viruses (85– 88). Vaccinia is at present among the most promising, owing to its high infectivity, safety report, and occasional risk of integration into host DNA genome (89). Vaccinia-based totally vaccines encompass encoding the vector with E7 fused to calreticulin, E7 fused to LLO, and SigE7 LAMP-1, in which E7 is linked to sorting signals and a lysosomal-related membrane protein (89,90). Tissue Antigen-HPV (TALLY-HO) is a vaccinia-based live vector vaccine that encodes mutated E6 and E7 oncoproteins for HPV16 and HPV18. Early clinical trials with TALLY-HO tested its functionality to result in HPV-particular cytotoxic T-cellular responses in patients with cervical cancers (89) and patients with HPV-related high-grade vulvar intraepithelial neoplasia (VIN III) and high-grade vaginal intraepithelial neoplasia grade two (VAIN II) (91). additionally, Tipapkinogen Sovacivec (TS) vaccine uses a changed Vaccinia virus Ankara (MVA) vector encoded with genes for HPV16E6/E7 and IL-2 (92). A phase II clinical trial in women with high-risk HPV-related CIN2/3 observed that the TS vaccine course ended in large histologic clearance of CIN2/3 than within the placebo group, no matter high-risk kind (92). a few special viral vectors beyond vaccinia have furthermore tested potential capacity to goal and clean HPV16 E6/ E7-expressing tumors and increase HPV E6/E7-specific immunity in preclinical models, with a few vaccines stepping into early phase of clinical trials (93). as an example, a HPV16 E6/E7 arenavirus based vaccine is presently being evaluated in HPV-related cancers in a phase I/II

clinical trial (NCT04180215). ultimately, Vvax001 is a Semliki forest Virus based HPV vaccine that has been tested for the therapy of patients with CIN 2/3 or cervical cancers (NCT03141463, (94)). no matter advantages to live-vector primarily based vaccines, native antiviral and antibacterial immune responses upon management can neutralize the vaccine in advance than it may categorical the intention antigen, precluding repeated vaccination. when the use of a viral vector, there can be an immune response set up closer to the vector itself, and there's opportunity of causing immunity towards the vector antigen instead than the encoded antigen, even though this will possibly be addressed with using a heterologous top-enhance approach. Likewise, as a stop result of vector specific immunity incited by means of using a principal vaccination, it is able to be hard to improve vaccination regimens using formulations that use the equal vector. those problems with the viral vector itself can therefore restriction HPV antigen-specific immune responses generated by method of repeated vaccination with the equal viral vector-based vaccines. moreover, immunocompromised and immunosenescent women and men can also moreover be at heightened risk for troubles with live-vector based vaccines, which can pose a protection problem, even though defective/single infection vectors can mitigate this concern (95).

1.1.2 Dendritic Cell Based Vaccine

A dendritic cell (DC) primarily based vaccine is a variant of a whole-cellular-based vaccine. Dendritic cells work as antigen-presenting cells (APCs) to serve as a bridge among innate and adaptive immunity (68). DC-primarily based HPV vaccines require loading the DCs with HPV antigens then turning inside the preloaded cells to the affected patient (97–103). DCs can enhance the efficiency of various antigen-specific therapeutic vaccines as they provide the patient or with the important thing immune cells to provoke adaptive immune responses which can be often limiting in advanced cancers (104). DC-based vaccines can be transfected with greater siRNAs to guard in competition to apoptotic molecules with the intention to lengthen the life of the cell and maximize immune effect (101,102). A phase I scientific trial located that pulsing DCs with full-length HPV16/18 E7 and keyhole limpet hemocyanin (KLH) then subcutaneously injecting the cells decrease again into the patient and properly tolerated in patients with level Ib and IIa cervical cancers (105). The approach additionally increased HPV-specific humoral and CD4+ T cell immune responses. however, a separate trial achieved in advanced cervical cancers discovered no regular widespread immune reaction (106).

Even as progress has been made to improve the efficacy of DC-based vaccines, they've pretty some obstacles. DC-based vaccines are technically demanding to supply on a large-scale. Secondly, various life-style methods might also moreover cause inconsistencies in vaccine quality and trendy comparison standards. third, DC-based vaccines do now not have the alternative of serving as an off-the-shelf vaccine. ultimately, the most effective route for DC vaccine administration to amplify the results elicited by the vaccine has now not been determined (98).

1.1.3 Peptide/Protein Based Vaccine

Peptide and protein based vaccines are safe, stable, and simple to supply at amount. Peptides and proteins derived from HPV antigens are taken up by of dendritic cells for presentation on MHC class I or II. Peptide/protein based vaccines could have weaker immunogenicity than live vector- based vaccines, and consequently can also need to be brought with adjuvants or lipids for enhancement (58). In distinction to peptide-based vaccines, protein-based vaccines may incorporate multiple human leukocyte antigen (HLA) limited cytotoxic T lymphocyte epitopes appropriate for general populations. In comparison, peptide-based totally vaccines can also totally be suitable for persons with nice HLA haplotypes, which limits their utilization in the general population (96). but, one potential answer for this quandary in peptide-based vaccination is to generate overlapping lengthy peptides encompassing the complete antigen(s) (107). presently, there are various peptide-primarily based vaccines beneath investigation for attainable use in competition to cervical cancers. as an example, ISA101 vaccine, a lengthy peptide vaccine that targets HPV16 E6 and E7 has been used in a phase I/II clinical trial in recurrent and metastatic patients with HPV-associated cancers (NCT02128126). whilst the early clinical trials on patients with HPV-associated vulvar and vaginal intraepithelial neoplasia using the ISA long peptide vaccines hooked up encouraging results (108,109), it's far now not clean but whether or not it works in a comparable method properly in patients with advanced cervical cancer. Tissue Antigen-Cervical Intraepithelial Neoplasia vaccine (TA-CIN) is a protein-based totally vaccine product of a single fusion protein to start out cell toxicity in opposition to antigens HPV16, E6, E7, and L2 proteins (110). TA-CIN is being evaluated for efficacy for cervical dysplasia, along side HSIL and LSIL. The vaccine has examined to be included and immunogenic in early phase medical trials (111–113). as a result of its tested safety and immunogenicity, TA-CIN has been used with imiquimod cream, a TLR7/8 agonist, for the remedy of grade 2 or 3 vulvar intraepithelial neoplasia (VIN) in hopes that TA-CIN could increase HPV16 E6 and E7 precise T effector cells (114). TA-CIN and

imiquimod in mixture produced lesion regression in a subset of patients, and increased CD8 and CD4 cell infiltration (86). currently it's being investigated along a DNA vaccine for the remedy of ASC-US, ASC-H, and LSIL (NCT03911076, NCT03913117), and for HPV16+ cervical most cancers patients (NCT02405221). every other protein vaccine named TVGV-1 can result in HPV16 E7CD8+ T cell responses in a preclinical model whilst delivered with CpG or GPI-0100 adjuvant (115). A phase II medical trial using TVGV-1 is ongoing in patients with HSIL (NCT02576561). Tumor antigens extraordinary than HPV encoded antigens have moreover been explored for the manipulate of cervical cancers. as an instance, a universal cancers Peptides peptide vaccine (UCPVax) is in modern times present procedure a clinical trial to determine its immunogenic efficacy in cervical cancers (NCT03946358). UCPVax is a special vaccine on trial for HPV-associated cancers as a result of the truth rather than targeted on an immune response in the direction of HPV antigen, UCPVax targets telomerases expressed through a variety of cancerous cells (116,117). UCPVax is used to stimulate CD4+ T cell activity in opposition to cancerous cells, with the goal of growing an immunotherapeutic vaccine that works in opposition to a multiple cancers types (118).

1.1.4 Nucleic Acid Based Vaccine

Nucleic acid based vaccines use RNA or DNA plasmid to deliver antigens to the immune system. Many candidate therapeutic HPV vaccines are DNA vaccines. DNA vaccines are evolved with the aid of putting the purpose antigen into a mammalian expression vector, and as soon as injected inside the body the encoded antigen is transcribed in vivo, allowing uptake by way of antigen imparting cells to present the antigens via MHC class I and II molecules. similar to peptide and protein vaccines, DNA vaccines are safe, convenient to produce, and stable. individuals again vaccinated with the plasmid (96). Even though there may be attainable risk that management of DNA encoding antigen oncogenes along with E6 and E7 may moreover lead to cellular transformation, most of the therapeutic HPV DNA vaccines employ mutated or shuffled E6 and/or E7 antigens, which gets rid of the issues for oncogenicity while remaining immunogenic (119).

One of the imperative obstacles for naked DNA vaccination is the low transfection efficiency in vivo. Electroporation has been used to enhance the DNA transfection efficiency in vivo to enhance the efficacy of naked DNA vaccination. for instance, GX-188E is a therapeutic HPV DNA vaccine, encoding a fusion protein consisting of an activator signal and FMS-like tyrosine kinase 3 ligand in addition to E6 and E7 of HPV16/18. preceding clinical trials have targeted on the usage of GX-188E for therapy of HPV-related CIN (NCT02139267, NCT01634503). so far, GX-188E has verified the capacity to promote lesion and viral regression in a significant fraction of CIN3 patients. Even though electroporation is transiently painful, this approach is properly-tolerated via study participants (120), and produces a large E6/E7 T cellular response (121).Some other therapeutic HPV DNA vaccine introduced through electroporation is VGX-3100, which is a DNA vaccine encoding HPV16 and HPV18 E6 and E7 antigens. phase I and II scientific trials in patients with HPV-high-quality CIN2/3 have confirmed the vaccine's protection, tolerability, and immunogenicity (122,123).

VGX-3100 demonstrated regression of precancerous cervical lesions and viral clearance in 48% of vaccine treated patients in evaluation to 30% of patients receiving the placebo manage (122). two phase III trials the use of VGX-3100 added via electroporation in cervical HSIL are in modern times underway (NCT03721978, NCT03185013). these days launched endpoints from the REVEAL 1 trial (NCT03185013) showed that for the modified aim to address (mITT) population (N=193) the important endpoint of histopathological regression of HSIL blended with virologic clearance of HPV16 and/or HPV18 at week 36 was 23.7% (31/131) in the treatment group, as opposed to 11.3% (7/62) within the placebo group (p=0.022; 12.4% difference in percent, 95%CI: 0.4,22.5) (124).

A comparable vaccine, INO-3112, carries HPV16 and 18 E6 and E7 antigens however with the addition of IL-12 cytokine. INO-3112 vaccine has verified its tolerability and immunogenicity in clinical trial as an adjuvant for chemoradiation in cervical cancers patients (125) and in HPV-associated head and neck cancers (126). Another method to enhance the performance of DNA vaccines is to appoint an intracellular concentrated on technique to enhance antigen presentation via MHC class I molecule to CD8+ T cells (127–129). For example, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is a therapeutic HPV DNA vaccine that uses the mycobacteria heat shock protein 70 to beautify DNA vaccine efficiency. The DNA vaccine encodes a fusion protein such as a signal peptide linked to a mutated HPV16 E7 protein and the mycobacteria heat shock protein 70 (HSP70).

The linkage of HSP70 to the E7 protein results in the linkaging on of the secreted E7 fusion protein to professional antigen supplying cells to beautify the cross presentation of the related E7 antigens (130). Early phase trials in CIN3 patients have confirmed pNGVL4a-Sig/ E7(detox)/HSP70 to be tightly closed for use (127). A comparable DNA vaccine, pNGVL4a-

CRTE6E7L2, employs calreticulin to enhance MHC class I presentation (129). The DNA vaccine stimulates the immune system to generate HPV16 antigens (E6, E7, and L2) specific immune responses (129). This vaccine will input medical trial with TA-CIN vaccination as booster (NCT03913117) and is nowadays being examined the usage of electroporation (NCT04131413). VB10.16 DNA vaccine is another example of naked DNA vaccine that may result in the targeted delivery of the encoded HPV antigens to expert antigen presenting cells to elicit immune responses to HPV16 E6 and E7 antigens. A phase I/II scientific trial in CIN2/three patients located the vaccine to be safe and properly tolerated, and the therapy elicited a CD8+ T mobile immune reaction in agonist to HPV16 antigen (131). RNA-primarily based vaccines have emerged as a new structure of vaccine for the control of infectious diseases and/or cancers. As opposed to naked DNA vaccines, RNA-based vaccines may be translated within the cytoplasm alternatively than delivered to the nuclei for transcription. Naked RNA vaccines work by means of the usage of injecting the affected patient with RNA that encodes a specific antigen to be introduced via the usage of APCs. the two in recent times licensed RNA-based totally vaccines for COVID-19 prevention signify a scientific triumph at the control of an infectious disease. The COVID-19 RNA based totally vaccines generate now not completely humoral immunity which may also be necessary for the manage of cancers that require cell immunity (132). there is one RNA-primarily based vaccine candidate for the treatment of HPV-related cancers named RNA-LPX that targets HPV16 E7 and has demonstrated the capacity to bring about lengthy time period antigen-particular CD8+ T cell responses in preclinical mouse models (133). A derivative of RNA-LPX, BNT113, is developed the usage of comparable mRNA structure and LPX technology, and it encodes every HPV16 E6 and E7. BNT113 is in modern times in a phase I/II scientific trial notably for HPV16-associated head and neck cancers patients, with intent to test the vaccine in patients with HPV16-associated cervical maximum cancers patients in the future (NCT03418480). RNA-based totally vaccines can additionally be derived from RNA viruses, often alpha viruses, collectively with the Sindbis virus, Venezuelan Equine Encephalitis virus, and Semliki woodland virus (87,134,135). The RNA strand is inserted with the aim antigen RNA, and it's far capable of self-replication, which leads to sustained antigen presentation and improved immunogenicity over special sorts of nucleic acid based vaccines (58). Crucially, RNA replicon vaccines lack structural genes, and therefore do no longer elicit a neutralizing antibody immune response which allows repeated vaccinations, and there's a low chance of chromosomal integration with host DNA or reconstitution of infecting virus (136).

In spite of blessings, RNA-primarily based vaccines will have low balance. In strive to stabilize the vaccine, RNA replicons and DNA vaccines can be combined right into a DNA-released RNA replicon vaccine, additionally termed “suicidal DNA” (58). “Suicidal DNA” induces apoptosis in cells that uptake the injected DNA to stop workable integration and transformation of the tainted cells (137). contemporary preclinical fashions using healing HPV suicidal DNA vaccines and RNA replicons have tested terrible immunogenicity; however, some techniques for boosting immunogenicity, along with the usage of flavivirus Kunjin vector or inclusion of HSP70, VP22, or genes encoding anti-apoptotic proteins, had been explored with preliminary nice results in preclinical models. (58,134,137–140). some other technique of using RNA for anti-cancer immunotherapy is to manage RNA to regulate APCs. DCs transfected with anti-apoptotic RNAs resisted cell lack of lifestyles and added antigens for longer than DCs from dendritic cellular-primarily based vaccines barring without the RNAs (140). similarly, gene gun transport of anti-apoptotic siRNAs along an HPV16 E7 DNA vaccine was once as soon as succesful to extend the lives of antigen offering cells and standard elicited higher antitumor activity than DNA vaccine administered barring siRNA in a preclinical model (141). even though siRNA techniques are now not strictly RNA vaccines, as they do now not encode antigen, they are able to possibly be used to raise exclusive immunotherapeutic vaccines for cancers remedy. no matter the protection of many nucleic acid and peptide vaccines, maximum show off restrained immunogenicity in advanced cervical cancer. even though numerous cervical cancers vaccines, which include ISA101 or VGX-3100, do screen immunogenicity as demonstrated through their medical efficacy in precancerous lesions (108,109,122), those vaccines alone may additionally now not be sufficient for the control of advanced cervical cancers due to primary or secondary cancers resistance mechanisms or an immunosuppressive tumor environment. people with low immunogenicity may additionally require strategies to enhance immunogenicity by means of way of adjuvants, co-treatments, more than one vaccinations, or delivery strategies. Many DNA vaccines for HPV-associated precancerous lesions and malignancies are introduced with the aid of electroporation (NCT01634503,NCT04131413). as a substitute, DNA prime determined by the usage of a protein or vaccinia vaccine increase strategies refers to the immunotherapeutic technique of a preliminary vaccination with a DNA plasmid, followed through method of a booster vaccination with a unique sort of immunotherapeutic vaccine. This mixture method doubtlessly elicits greater appropriate immune responses than each vaccine by itself (142). nowadays clinical trials are investigating the method of combining a DNA vaccine with TA-CIN fusion protein vaccine for HPV16+ with abnormal cytology lower than high grade lesion (ASC-US/LSIL) (NCT03911076, NCT03913117).

Each plasmids and the TA-CIN protein improve vaccine have shown safety profiles. Priming with DNA vaccine pNGVL4a-Sig/E7(detox)/HSP70 accompanied by way of increase with stay-vaccinia vector based totally completely vaccine TALLY-HO are being investigated for potentiality therapeutic use in competition to HPV16+ CIN3 (NCT00788164). Combined cure with TALLY-HO vaccinia vaccine and TA-CIN protein vaccine has moreover proven confined immunotherapeutic outcomes in HPV-associated VIN (84).

1.2 Adoptive T Cell Treatment

Adoptive T cell therapies (ACT), or T-cellular based totally vaccines, is the exercising of casting off T cells from the host and expanding, enhancing or choosing T cells for tumor antigen reactivity ex vivo, then re-infusing them once more into the host so that the T cells will target tumor antigens to promote tumor regression (143,144). There are 3 most important groups of ACT: tumor-infiltrating lymphocytes (TILs), engineered T-cellular receptor T cells (TCRs), and chimeric antigen receptor (CAR) T cells (145). cutting-edge efforts to aim HPV E6 and E7 with healing vaccines for the treatment of cervical cancers have but to publish tremendous success in treating advanced cervical cancer. as the perception of tumor immunology has expanded exponentially over the remaining three decades, the problematic relationships among tumor cells, the tumor micro-environment, and immune cells, consisting of cytotoxic T cells, helper T cells, and regulatory T cells, have totally begun to come to be untangled. recent research at the multitude of outcomes and heterogeneity of innate myeloid effector cells have suggested the importance of antitumor myeloid populations in cancers development. numerous studies have related certain myeloid cell types with affected character survival and responses, indicating that myeloid cells in the TME is although mature for in additional investigation (146). In spite of this ongoing research, T cells are appeared to be foremost effector cells of immune-mediated cancers regression. for that reason, ACT therapies are especially appealing. ACT has been proven to facilitate whole clinical responses in some patients with B-cellular malignancies and metastatic melanomas; however, its achievement in epithelial malignancies has been limited and it remains to be taken into consideration whether or not ACT can mediate the regression of metastatic cervical cancers (147). Despite the fact that ACT is a promising cancers remedy technique and shows encouraging results in preclinical and clinical trials (145), there's however an awesome deal paintings to be finished for solid tumors such as cervical cancers. HPV-related cervical cancers is theoretically a strong candidate for ACT therapy. ACT calls for a tumor-specific antigen for the T cells to target, and cervical cancers specific HPV oncogenes. Those HPV oncogenes can serve as goals for ACT therapies methods with tumor homing and low hazard of the treatment targeting uninfected host tissue, a frequent toxicity associated to act (143). numerous ACTs had been tested in preclinical and scientific trials. ACTs ignore the immune reliance on sensible host dendritic cells and APCs to spark off T cells, and as an alternative ACTs adjust T cells without delay. moreover, ACT can be built to overcome immune tolerance and incorporate changed tumor-specific T cells, which may additionally not give up end result from traditional therapeutic vaccination (148). A further advantage of ACT is their capability to behave as particularly custom designed healing remedies with sizable clinical potential (147). no matter possible advantages, ACTs include drawbacks. these therapeutic methods come with risk of cytokine release syndrome (CRS), neurotoxicity, and off-tumor targeting on toxicity (143,149). previous to injecting the patient with these therapeutic procedures, they may also require temporary lymphodepletion (one hundred fifteen). however, the individualized and immunogenic ensures of ACT remedy alternatives ensure they remain one of the most interesting immunotherapies for cancers studies.

1.2.1 Tumor Infiltrating Lymphocytes

Tumor infiltrating lymphocytes (TILs) are T cells isolated from a tumor mass, improved ex vivo, regularly cultured with IL-2 to allow reactive tumor antigen selection, then infused back into the affected person (143,145,150). TILs have been demonstrated to manage tumor regression in patients with metastatic cancer (70,151). lately, TIL treatment has been investigated for numerous extraordinary varieties of cancers inclusive of gastrointestinal, lung, and HPV-related malignancies (152). TILs selected for HPV oncogenes E6 and E7 have been demonstrated to purpose tumor regression in patients with metastatic cervical cancers (147). Efficacy of TIL remedy can be prolonged by way of enhancing the reactivity towards defined cancers antigens (150). unluckily TILs are hard work in depth, have low rates rates, and feature impaired performance in tumor micro-environments that are overly immunosuppressive (72). TIL treatment is labor and time extensive because the remedy requires isolating tumor-reactive T cells from excised tumor and expanding them. There have been several trials that have investigated the usage of TILs in cervical cancers. A preclinical study isolated mononuclear cells from tumor draining lymph nodes from patients with HPV-associated cervical cancer. the following cells were cultured for HPV E6 specificity, then analyzed the usage of assays, flow cytometry, and tested for CD25 and FoxP3 expression. specific A phase II medical trial investigated the usage of TILs in HPV-related cancers.

After lymphocyte depleting chemotherapy, TILs have been chosen for HPV E6/E7 reactivity and administered to the patients with aldesleukin. three of nine patients confirmed an objective tumor reaction, two patients who had responses that lasted over a 12 months, and further toxicity used to be as soon as restricted (147). but, there is a possibility that though the TILs had been chosen for HPV-particular antigen reactivity, cervical cancers cells do specific extraordinary tumor antigens which can need to have moreover been focused by using the improved T cells (72). Future research the usage of TILs which can be completely HPV-specific have to elucidate whether or not the regression used to be once by virtue of entirely HPV-targeting (44). An ACT method similar to TIL administration is Cytokine added on killer cellular cell (CIK) remedy. CIK therapy, instead than the usage of immune cells placed in tumor tissue, cultures and expands peripheral blood mononuclear cells (PBMCs), and then infuse the affected individual with the killer cells. This method is less complicated than exclusive ACT techniques, and though lets in tumor homing and spares maximum non-cancerous host tissue, and has proven efficacy in several solid and hematologic malignancies (144). inside the context of cervical cancers, CIK remedy along with radio-chemotherapy tested momentary efficacy to cope with cervical cancers (144) warranting further investigation.

1.2.2 Engineered T cell Receptor T cells

An alternate method to ACT is using engineered T cell receptors (TCRs). TCR treatment is special from TIL treatment as alternatively of increasing tumor-specific T cells that have been already present in the body, host derived T cells are changed by the usage of genetic engineering to specific a unique tumor-targeting T cell receptor (145). TCR cells may be moreover used to help ignore the aid of immune tolerance of the tumor. these cloned, tumor-specific TCR T cells that recognize particular antigen peptides positive to each MHC I or II are infused again into the host after growth (152). TCR remedy depends on generation of T cell receptor α and β chains that recognize tumor goals, and the expression of those engineered TCR molecules in autologous T cells (149). therefore, the functionality of engineered TCR cells to become aware of tumor cells is based upon at the cell surface abundance of alpha/beta heterodimer and receptor affinity of the target antigen (149). changed promotors or mutations in the α and β chains are two feasible techniques to optimize the efficacy of engineered TCR T cells (149). Engineered TCRs are then activated by the identical signal transduction mechanisms as non-engineered T cells (152). emerging proof appears to show off the functionality of engineered TCR T cells to recognize E6 and E7 magnificent tumor cells (145). A completed phase I/II trial investigated the use of E6 engineered TCR T cells in HPV16+ cancers, brought along with lymphocyte depletion and IL2. There had been no integral negative activities, and the effects encouraged that E6 TCR treatment may additionally reason regression of HPV associated epithelial cancers, and warrants similarly find out about (155). numerous unique clinical trials are investigating the use of HPV mycoprotein TCR T cells in cervical cancer, and are set to be finished over the subsequent couple of years (NCT03578406, NCT04476251, NCT02858310). despite ongoing clinical trials, maximum fulfillment with TCR cures have centered hematologic malignancies, and common TCR therapeutic effect on solid tumors as well as HPV related malignancies is underexplored (93).

1.2.3 Chimeric Antigen Receptor (CAR) T Cells

CAR T cell treatment is a department of ACT that requires genetic redirection of T cellular specificity by way of using the advent of a synthetic attention form to the host T cellular referred to as a chimeric antigen receptor (CAR) (152). A major benefit to CAR T cell remedy is that it does no longer require an intact MHC presentation tool on cancers cells. this is good sized because the immunosuppressive TME can downregulate of MHC presentation (156,157), which renders one of a kind antigen specific immunotherapy that assume MHC presentation ineffective. CAR T cells can consequently be used on tumors which might be faulty for antigen presentation and processing (152), no longer like TILs, TCR remedy, or immunotherapeutic vaccines. CAR function objectives to provide, consequently, a remarkable co-stimulatory signaling to spark off effector T cells (156). automobiles consist of an extracellular antigen cognizance domain, a hinge area, a transmembrane location (TM), and an intracellular vicinity (158). The extracellular antigen interest region is derived from a single chain variable fragment (scFv) isolated from an antigen-particular monoclonal antibody (mAb), which lets in the engineered T smartphone to bind to antigens expressed on tumor cells with preserved affinity and specificity. The hinge vicinity allows vehicle flexibility, ensures proper positioning of the binding vicinity in the course of scFv-antigen interplay, and transduces vital indicators. The transmembrane region influences auto mobile T telephone characteristic, and it is derived from CD3-z, CD4, CD8, OX40, or H2-Kb. The intracellular vicinity which offers the signal is derived from lymphocyte signal initiating molecules. The sign then activates the effector feature of the car T cells (156,158). presently four generations of car-T cells exist, and maximum had been utilized in hematological cancers as a substitute than stable tumors (a hundred and fifteen). After the first generation showed horrible

persistence and clinical efficacy, one and two co-stimulatory molecules have been added to the 2d and 1/3 generation, respectively (for assessment see (158)). The 0.33 era cars were constructed upon the advanced T cell antitumor immunity of the 2nd generation, with the addition of multiplied cytokine production and extra tumor increase inhibition in mice (156). No matter those additions in the 1/three technology, second era car T mobile phone treatment is used more broadly in clinical trials owing to the fact they've a bigger activation threshold, which outcomes in tons less on-target/off-tumor cytotoxicity in everyday tissues (one hundred thirty). Finally, fourth generation auto mobile T cells embody a cytokine expression cassette on the auto mobile bring together vector, resulting in a chimeric T mobile redirected for well-known cytokine-mediated killing (TRUCKs) (156). medical trials with second era CD19 automobile T remedy has had promising effects for hematological malignancies, resulting in CD19 vehicle T cell remedy (CTL019) being categorised a “breakthrough” treatment through the FDA (158). however, there are a long way fewer makes use of of CAR T treatment in robust tumors. there may be at present one ongoing trial investigating the usage of CAR T cells in cervical cancer. unlike many exclusive cervical maximum cancers trials, as an opportunity than using an HPV antigen as a purpose for immunotherapy, the CAR T cells will be engineered for sufferers with GD2, PSMA, Muc1 or Mesothelin excellent cervical most cancers (NCT03356795, table two). it's miles theorized that the histopathological shape and robust immunosuppressive environment of robust tumors limit the efficacy of CAR T cell remedy. those obstacles have inspired a number of trends in CAR-T phone remedy closer to strong tumors, in conjunction with cytokine launch, and purpose TAA change (158). nevertheless, till now CAR T cell treatment has now not been verified to be an fantastic immunotherapeutic remedy for cervical cancer.

2. Strategies to Reverse Immunosuppression and to Enhance Effector Immune Cells in the TME

Under normal, non-cancerous conditions, immunoregulatory elements such as immune checkpoint inhibitors, preserve self-tolerance, forestall autoimmunity, and shield health cells from immune assault or extended infection at some stage in infections. During this homeostasis, cell immunity is regulated via activation alerts (co-stimulatory molecules, as introduced by means of APCs) as properly as inhibition indicators (immune checkpoints) (75). As tissues emerge as cancerous, they bear immune editing, the technique by means of which cancerous cells are in a position to evade immune system elimination, enabling unchecked growth and spread. Cancer cells regularly take advantage of naturally going on immune regulators to get away immune surveillance and create an immunosuppressive tumor micro-environment (TME), whilst downregulating anti-cancer undertaking with the aid of effector T cells. An essential strategy to immunotherapy is to increase and guide extant immune cells inside the TME. As hostile to improving T cell priming, which enhance the variety of T cells, augmenting effector immune cells pursuits mechanisms that promote pre-existing cytotoxic recreation and prevent mechanisms that restriction effector cell activity. These techniques are no longer specific for any antigens, and do now not contain in the de novo technology of cervical cancer-specific T cells.

2.1 PD-1 and CTLA-4 Immune Checkpoint Blockades in Cervical Cancer

Immune checkpoints might also be modulated by using both agonist or antagonist monoclonal antibodies used to decorate T cell activation and get rid of inhibition of T cell activation respectively in order to reactivate T cells to attack tumors (74). A frequent method to many cancers immunotherapies is the use of antagonist antibodies that goal programmed cell death receptor (PD-1) and cytotoxic T-lymphocyte related antigen 4 (CTLA-4), which have been significantly studied (159,160). The PD-1/PD-L1 axis is a major immune checkpoint system. PD-1 is expressed on the surface of effector immune cells that binds programmed cell death receptor ligand (PD-L1) expressed via tumor cells or immunosuppressive cells in TME. The FDA has accepted PD-1 inhibitory antibody pembrolizumab for cervical cancers following the KEYNOTE-158 clinical trial, an extensive harbinger for its viable utility for metastatic/recurrent cases. In the KEYNOTE-158 trial, 98 patients with before dealt with superior cervical cancers had been given 200mg of pembrolizumab each and every three weeks till progression, intolerable toxicity, patient/physician decision, or two years had passed. Of these patients, 82 had PD-L1 positive tumors. The overall response charge (ORR) used to be 12.2%, and all of the patients who skilled entire or partial responses had PD-L1 positive tumor. For sufferers who acquired at least one chemotherapy treatment, the ORR rose to 14% (76).

In addition to demonstrating the therapeutic advantages of pembrolizumab alone, the improved ORR for sufferers who acquired standard-of-care chemotherapy suggests the workable of combining immunotherapy techniques with different most cancers therapeutic modalities, in addition mentioned in a later section. PD-L1, the ligand for PD-1 that can be exceptionally expressed on tumor cells, is any other most important goal molecule for antagonist monoclonal antibody immune checkpoint inhibitor (ICI) therapy. When PD-L1 binds PD-1, T cells are deactivated. Binding of the PD-1/PD-L1 axis consequences in the inactivation of

many immune cells, consisting of CD8+ T cells (161). Under regular conditions, PD-L1 is precipitated through IFN-gamma and works to shield surrounding tissue from unwarranted and extended T cellphone mediated cytotoxicity (160,161). Several research have indicated that virus-induced cancers, and greater specifically, HPV-associated cervical cancers and cervical intraepithelial neoplasia, can also upregulate PD-L1 (161–163). This upregulation was once no longer located in non-HPV contaminated benign cervical tissues. Current accredited anti-PD-L1 antibodies consist of durvalumab, avelumab, and atezolizumab, even though none have but been permitted for use in cervical cancer. Several different trials to date have verified the practicable anti-tumor therapeutic gain of the use of ICIs for the therapy of cervical cancer. PD-L1/PD-1 inhibitors have proven promising universal response prices in cervical most cancers patients (161). One case find out about counselled that chemotherapy in aggregate with pembrolizumab is nicely tolerated and doubtlessly advantageous in stage IV cervical most cancers (164). This discovering was once corroborated by means of a learn about on human medical samples earlier than and after chemotherapy that located that cisplatin primarily based chemotherapy can upregulate PD-L1 in cervical cancer, and that the use of checkpoint blockade immunotherapy might also thereby useful resource tumor regression (165). Nivolumab and pembrolizumab have each validated scientific gain in medical trials, and they are properly tolerated in recurrent or metastatic cervical most cancers sufferers (166,167). Alternatively, CTLA-4 is expressed on the floor of T cells and, as soon as sure to its ligands CD80 or CD86 that are located on APCs, downregulates T cell cytotoxicity (168). CTLA-4 contributes to the attenuation of activating T cells (169). This axis additionally performs an enormous function in autoimmune ailments (170), however in the immunosuppressive TME the inhibition of CTLA-4 by using ICI antibodies (Ipilimumab, tremelimumab) helps reverse immune device suppression and promotes tumor clearance (168,172). Whereas PD-1/PD-L1 blockade features specially by using slowing CD8+ mobile exhaustion, CTLA-4 ICI features by means of activating new T cells and suppressing Tregs (74). An ongoing section I/II clinical trial in patients with metastatic/recurrent cervical cancers shows that ipilimumab, a CTLA-4 inhibitor, is nice tolerated, and can promote immune activation (172). Other ongoing medical trials are investigating the use of exclusive immune checkpoint inhibitors in cervical cancers (NCT03192059, NCT02257528, NCT03508570, NCT03833479, NCT04256213) and in patients with cervical, vaginal, or vulvar HPV-associated lesions (NCT04211103). Furthermore, ICIs can be used in tumors regardless of whether or not they are HPV-associated or now not due to the fact they can potentiate each HPV-specific T cells and neoepitope-specific T cells. Therefore, numerous medical trials the usage of ICIs consist of cervical cancer, however do now not require particular HPV-association or status. Clinical trials use the immunotherapeutic pembrolizumab in advanced solid tumors, which include however now not restricted to cervical or gynecologic cancers (NCT02054806, NCT02628067. One medical trial pursuits to deal with patients with advanced cancers the usage of an aggregate of anti-PD-L1 monoclonal antibody (durvalumab) and anti-CTLA-4 monoclonal antibody (tremelimumab) (NCT01975831). Although ICIs are commonly well-tolerated, immune checkpoint inhibition can purpose toxicities and immune associated adverse events (ires), which are greater precise to immunotherapy and are no longer related with different types of most cancers remedy such as radiotherapy or chemotherapy. Common toxicities related with immune checkpoint inhibition consist of diarrhoea, colitis, rash, thyroid dysfunction, lowered appetite, fatigue, hepatitis, and pneumonitis (74,173). Other much less frequent ires encompass arthritis, myositis, vasculitis, polymyalgia rheumatic-like syndrome, systemic sclerosis, sicca syndrome, and systemic lupus, however these prerequisites are extra frequent in indivduals with pre-existing autoimmune problems or autoantibodies (174).

2.2 Other Checkpoints to Augment Effector T Cells

In addition to antibodies concentrated on the PD-1/PD-L1 axis and CTLA-4, different therapeutic antibodies for the remedy of cervical most cancers are additionally being actively investigated. Agonist antibodies to assist functioning of OX40, GITR, and TLR3 have been explored for the therapy of cervical cancers, though no such remedy has but been authorized for use in cervical most cancers (NCT04198766, NCT03739931, NCT03241173, NCT03799003, NCT03126110, NCT02643303). OX40 is expressed by using activated immune cells, and the use of an agonist antibody can facilitate its T cell stimulatory action and extend numbers of activated effector T cells (147). Studies in a preclinical cervical cancers model (TC-1) verified that OX40 agonists would possibly have therapeutic advantage for HPV16-associated cancers, however that aggregate with PD-1 antagonist antibodies might also be detrimental (176). Early effects from a medical trial of OX40 agonists in patients with solid tumors, which include each HPV-positive and –negative cervical cancers patients, determined no early medical response, however did end result in will increase in Ki67+ CD4 and CD8 T cell populations and a 60% discount in OX40+ FOXP3+ regulatory T cell populations (177). Enhanced expression of Glucocorticoid-Induced TNFR-Regulated protein (GITR) via immune cells in HPV-positive human cervical tissue samples suggests that GITR can serve as a disease development biomarker. In addition, it is a goal for GITR antibody immunotherapy (178), as GITR agonists can improve effector T cells through activating CD25, IL-2, IFN-γ,

and inhibit suppressive Treg functioning (179). Several non-cervical most cancers preclinical fashions have verified the attainable advantage of GITR immunotherapy as well (151). In addition to PD-1 and CTLA-4, different antagonist antibodies beneath investigation consist of those for LAG3, TIM3, CD39, and A2AR (NCT03652077, NCT03538028, NCT02488759, NCT04306900, NCT03454451). High LAG3 can inhibit cytotoxic T cell functioning and promote Treg immunosuppression, in addition to a myriad of different features that reduce cytotoxic T cell functioning, and preclinical models have confirmed multiplied tumor unique immune responses to anti-LAG3 antibodies (180). LAG3 is a promising goal for immunotherapy due to the fact cervical cancers tissue samples, specifically HPV-associated cervical cancers samples, have tested excessive LAG3 expression (181). Likewise, cervical cancers samples have excessive TIM3 expression, and TIM3 may additionally promote metastasis of cervical most cancers (182). TIM3 is expressed on a couple of T telephone types, and its expression is related with extraordinarily suppressive Tregs and can sign exhaustion of cytotoxic T cells (183). Several preclinical non-cervical cancer models have confirmed the possible advantage of anti-TIM3 immunotherapy in cancers with excessive TIM3 expression (183). Finally, CD39/CD73 and A2AR molecules are carefully related: transmembrane CD39 helps adenosine production, which in flip alerts Adenosine 2A Receptor (A2AR) to downregulate immune system functioning. Therefore, inhibiting a step in this pathway should beautify T cell functioning. HPV16 positive CIN affected person samples have excessive CD39 and CD73 expression (184), and cervical cancers cell lines in a similar fashion displayed CD39 and CD73 expression (185). CD39 expression can be upregulated on tumor cells or expressed on T cells, consisting of Tregs, to downregulate immune device Anti-CD39 immunotherapy is nonetheless under development, and medical trials have begun exploring its use for antitumor immunity (186). However, current findings propose that CD39 is no longer continually a marker for immunosuppression. CD39 has been related with tumor-infiltrating CD8 and CD4 effector T cells that can understand overexpressed self-antigen or neoantigens (187,188). CD39 expression has been related with increased medical prognosis in colorectal, lung, and head and neck cancer, and extra recently, HPVreactive CD39+/CD4+ T cells have been related with accelerated medical prognosis in HPV-associated vulvar, oropharynx, and cervical cancers (189). CD39 may additionally now not solely be a marker of immune exhaustion. Monoclonal antibodies for CD39 may also as a result have a myriad of anti-tumor mechanisms to replicate its extensive array of functioning throughout classes of immune cells, from B cells, Tregs, innate immune cells, and tumor-infiltrating non-Treg CD4 and CD8 cells (188). Likewise, preclinical cervical cancers models have counseled that A2AR may additionally impact the immunosuppressive cervical surroundings (190), suggesting that A2AR antibodies might also be really helpful immunotherapy (191).

2.3 Suppressive Immune Cells

An extra immunotherapeutic method is to goal immunosuppressive and cancer promoting elements arising from the cervical cancers cells, especially inhibiting suppressive immune cells and limiting positive immunosuppressive metabolites and stroma molecules. Immunotherapies that goal immunosuppressive elements inside the tumor micro-environment can reverse immunosuppressive environments, forestall in addition tumor growth, and allow immune cells to apprehend cervical cancers cells. Targeting immunosuppressive elements in the TME does now not count number upon cervical cancers unique antigen presentation. Although the majority of cervical cancers are related with hrHPV types, this kind of immunotherapy does now not necessitate the era of HPV antigen-specific T cells and can work on a broader vary of cancers. Nevertheless, such immunotherapeutic approach probably can be used in conjunction with a method to enhance tumor-specific immunity to similarly enhance therapeutic antitumor impact. Some cervical immunotherapies can goal suppressive immune cells that exist inside the TME, which include Tregs, tumor related macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) (192). Strategies to forestall suppressive immune cells from gathering close to tumor encompass c-MET inhibitors (193), IL-23 inhibitors (192) and PI3K receptor inhibition (194). The c-MET/HGF pathway has been related with negative prognosis in cervical cancers (195). IL-23 has been related with pro-tumor environments, mainly via the induction of Th17 cells (196), and cervical malignancies have been related with extended stages of the cytokine (196–198). The PI3K/Akt/mTOR pathway moreover has been recognized as a manageable therapeutic goal for cervical cancers (199– 203). Several medical trials focused on this component of the tumor micro-environment are being explored. Cervical most cancers cells additionally manipulate metabolites inside the TME, for instance by means of arginases and IDO. Arginase inhibits T cell and NK cell proliferation inside the TME, and its upregulation has been related with cervical cancers immunosuppressive environments (204,205). INCB0011158 is being used in a medical trial for solid tumors, which include cervical tumors, to decide whether or not inhibiting arginase enzymatic undertaking can reverse immunosuppression (NCT02903914). Another enzyme, indole-amine dioxygenase 2,3 (IDO), suppresses anti-cancer immune response with the aid of various downstream consequences (206). In a preclinical cervical most cancers model, the downregulation of IDO suppressed tumor growth and boosted NK cell activation (207). In a learn about of human cervical

cancers, a widespread variety expressed IDO or had co-expression of PD-L1 and IDO (208). Taken with the preclinical model data, it seems that focused on the immunosuppressive metabolite IDO inside the TME should probably affect cervical cancers malignancies.

2.4 Angiogenesis Inhibition

Preventing vascularization of tumor tissues slows growth of tumors, which offers the immune system a higher risk of bringing the cervical cancers cells beneath control. Bevacizumab is an antiandrogenic molecule that inhibits vascular endothelial growth factors (VEG), thereby stopping the growth and maintenance of new blood vessels. Fast developing cancerous cells that require vascularization can be inhibited by way of the use of bevacizumab. In 2014, bevacizumab used to be authorised with the aid of numerous nations for its use in advanced cervical cancers following a successful medical trial, GOG 240 ((209), NCT00803062). Currently, chemotherapy in aggregate with bevacizumab is the first-line remedy for therapy of recurrent/metastatic cervical cancers (209,210). Given the efficacy of bevacizumab for cervical cancers, anti-angiogenetic pills are nevertheless being explored and in combination with different anti-immunosuppression treatments, such as atezolizumab (NCT02921269, NCT03074513), or M7824, which is a PD-L1 and TGFβ inhibitor (NCT04551950). Clinical trials are additionally inspecting the manageable of anti-VEGF remedies in mixture with chemotherapies: a phase I clinical trial the usage of Bevacizumab and paclitaxel-albumin stabilized nanoparticle formula chemotherapy is underway in stage IV gynecological cancers (NCT02020707).

3. Combinational Therapy

Combining immunotherapeutic techniques can be advantageous. Rather than fully improving antigen specific T cells, concentrated on immunosuppression in the TME, or assisting effector immune cells, deciding on a couple of techniques can end result in a broader, extra fantastic approach. Combinational immunotherapy can include of one or more immunotherapeutic strategy, or an immunotherapeutic approach in aggregate with standard-of-care treatment plans such as chemotherapy or radiation therapy. Since some trendy of care remedies might also end result in heightened immunosuppression (211,212), combining immunotherapies to reverse the aspect impact may also have a synergistic antitumor effect. As mentioned, antigen particular immunotherapeutic techniques for cancers remedy can currently undertaking due to the fact they require an intact and strong immune machine to manipulate, which advanced cervical cancers patients might also lack. Thus, therapeutic HPV vaccines concentrated on established HPV infections and/or precancerous lesions to stop malignant development can also signify an easier less difficult undertaking than concentrated on advanced cervical cancer. Alternatively, combinatorial techniques with different immune modulation can also turn out to be essential methods to improve the immune system in order to satisfactory fight advanced cervical cancer. Combinational treatment options can consist of mixture of distinct immunotherapeutic approaches, aggregate of immunotherapy with chemotherapy, and mixture of immunotherapy with radiotherapy.

3.1 Combination of Immunotherapeutic Approaches:

Antigen specific immunotherapeutic vaccines for most cancers remedy can current a venture due to the fact they require an intact and robust immune system to manipulate, and every can come with respective drawbacks, for occasion DNA vaccines can have low immunogenicity, or vector-based vaccines may additionally no longer be in a position to be administered greater than once. Thus, combining antigen specific therapeutic vaccinations with antibodies to reverse immunosuppression and guide effector T cells may also end result in a booster immune response. In general, antibody-based immunotherapy can assist reverse an immunosuppressive TME which clears a direction for a vaccine to generate a robust antitumor impact and decorate the immunogenicity of any other case weakly superb treatment (213,214). Clinical trials in more than one cancers have determined that mixture therapy can improve immune responses whilst protecting appropriate safety and tolerability (213). Within HPV-associated tumors, numerous preclinical research have indicated that combining an anti-PD-1 antibody with therapeutic HPV16 E6/E7 vaccines outcomes in increased tumor clearance and large wide variety of CD8+ T cells (215,216). Multiple clinical trials combining HPV antigen-specific vaccines with antiPD-1/anti-PD-L1 have been initiated. Priming with Ad/E6E7 and boosting with MG1-E6E7 virus-based vaccines administered in aggregate with atezolizumab is presently being evaluated in a Phase I clinical trial for HPV-associated cancers (NCT03618953). Another clinical trial performed in 24 patients with HPV-positive cancers determined that ISA101 vaccine in mixture with nivolumab had ideal universal response charges and durability (217). Notably, this trial confirmed the mixture remedy had a median universal survival (OS) of 17.5 months, and a 12-month OS of 70%, which is greater than PD-1 antibody therapy alone by using almost a factor of two (217).

GX-188E, an HPV16/18 E6/E7 DNA vaccine delivered with electroporation, is being examined in a phase I/II trial alongside Keytruda (pembrolizumab) in HPV-associated advanced cervical cancers (NCT03444376). Patients said manageable side outcomes and established encouraging antitumor activity, corroborating the speculation that combining therapeutic HPV vaccines and ICIs may also be a doubtlessly promising therapy (218). Other ongoing trials combining peptide vaccines and ICIs consist of Universal Cancer Peptide Vaccine (UCPVax) and atezolizumab (NCT03946358) and PDS0101 multi-peptide HPV16 vaccine, IL-12, and M7824, a PD-L1 antibody (NCT04287868). INO-3112 is presently being used in a clinical trial alongside Durvalumab for HPV-associated cancers, which includes cervical cancers (NCT03439085). VB10.16, a therapeutic HPV DNA vaccine, is additionally in a medical trial for patients with metastatic, recurrent, and persistent cervical cancers the use of atezolizumab as an adjuvant due to the upregulation of PD-L1 in cervical cancers (NCT04405349). Few ACT cures have proven vast efficacy towards solid tumors, such as cervical cancer. Some ACT treatment options require immunodepletion of naturally circulating lymphocytes prior to infusion and administration of IL-2. An ongoing phase II trial of TIL infusion remedy and IL-2 following pembrolizumab in patients with recurrent, metastatic, or persistent recurrent cervical cancers is underway (NCT03108495). Alternatively, Vigil is a structure of ACT that amplifies T cells extracted from affected person tumor, transfected with an immune-stimulatory cytokine, GM-CSF, and a hairpin RNA that knocks down the expression of quite a few boom elements (TGFβ-1 and TGFβ-2), before being reinfused in the patient. The aggregate of Vigil and atezolizumab is being investigated for gynecological cancers (NCT03073525). Combining ICI antibodies that intention to inhibit one of a kind immunosuppressive elements and to decorate T cell functioning for the remedy of cervical cancers is presently ongoing, as it is viable to modulate the TME and extend antitumor immunity besides consideration HPV goal antigens. For example, a phase I trial in patients with breast, ovarian, colorectal, renal, or cervical cancers is investigating the doable advantages of combining durvalumab (anti-PD-L1) with tremelimumab (anti-CTLA-4) (NCT01975831). A medical phase I/II find out about is exploring the use of specific combination of monoclonal antibodies in virus associated cancer, together with cervical cancers (NCT02488759). The learn about will use nivolumab (a PD-1 inhibitor) in mixture with both ipilimumab (CTLA-4 inhibitor), relatilmab (anti-LAG-3 antibody), or daratumumab (anti-CD38).

3.2 Combination of Immunotherapy with Chemotherapy

To date, there have been constrained research on the viable gain of combining chemotherapy and vaccines for cervical cancer. Combination of therapeutic HPV vaccine with chemotherapy has been proven to enhance the therapeutic HPV impact with the aid of lowering the adverse immunosuppressive TME in a preclinical model (219). A medical and a separate preclinical learn about determined that chemotherapy, such as carboplatin, paclitaxel, and cisplatin, can minimize immunosuppressant myeloid cells and promote inflammatory myeloid cells in HPV-associated tumor areas (220,221). This chemotherapy-reduction of immunosuppressant cells and promoting of effector cells can foster an environment for a vaccine to enhance antigen-specific T cells. One virus based totally vaccine, TALLY-HO, has been efficiently used in conjunction with chemotherapy (cisplatin) in a preclinical TC-1 mouse model for HPV-associated cancers (223). Furthermore, one c; clinical trial administered ISA101 peptide vaccine with carboplatin and paclitaxel in women with advanced, recurrent, or metastatic cervical cancers in a phase II study. Overall, 77 patients obtained treatment. Nearly 43% of patients confirmed tumor regression, and patients specific HPV16 specific T cell response (192). The aggregate was once discovered to be tolerable, and the commentary that chemotherapy decreased myeloid cells used to be demonstrated (220). Despite these successes, a phase II clinical trial combining live-attenuated listeria vaccine ADXS11–001 with chemotherapy (cisplatin) did no longer locate the mixture therapy to be any extra nice than therapeutic HPV vaccine remedy alone (223).

ACT treatment plans coupled with chemotherapy is moreover being examined for the therapy of HPV-associated cancers, along with cervical cancers cervical cancer. Metastatic cervical most cancers patients who had formerly been handled with platinum-based chemotherapy or chemoradiotherapy had been given one infusion of IL-2 and HPV16/18 E6/E7 TILs. Of 9 patients, three had goal tumor responses, with two patients that skilled whole responses for 22 and 15 months (147) (NCT01585428). However, no patients skilled an entire tumor response and solely two patients skilled a partial response after therapy with E6 TCRs, aldesleukin, fludarabine, and cyclophosphamide (NCT02280811). An ongoing trial in patients with HPV-associated cancers is the use of HPV E7 TCR cells with fludarabine, clyclophosmphamide, and aldesleukin, and outcomes are anticipated in 2026 (NCT02858310). As referred to above, chemotherapy can lead to a detrimental immunosuppressive TME, and consequently ICIs can probably reverse immunosuppression when used in mixture with chemotherapy to enhance therapeutic antitumor effect. Investigators are additionally gaining knowledge of combining antibody immunotherapies with solely chemotherapy

(NCT02914470, NCT04188860, NCT04238988, NCT03912415, NCT03912402, NCT03518606, NCT03367871). For example, an ongoing phase II medical learn about is investigating the use of pembrolizumab and cabozantinib in 39 patients with recurrent/metastatic/persistent cervical cancers (NCT04230954).

3.3 Combination of Immunotherapy with Radiotherapy

Radiotherapy in aggregate with ICIs can be really helpful due to the fact radiation can motive cell inflammatory damage, which prompts activation of tumor specific effector T cells. The inclusion of ICIs on top of this inflammation may additionally beautify the consequences of these T cells by using lowering the inhibitory consequences of the TME for a synergistic antitumor immune impact (224). One phase II medical trial makes use of radiation remedy in mixture with atezolizumab in patients with advanced, recurrent, or metastatic cervical cancers (NCT03614949). Several different medical trials are underway to check out the use of immunotherapeutic antibodies focused on the TME for cervical cancers with radiation remedy (NCT03452332, NCT03277482). As immune system activation, suppression, and the TME are complicated, combinational techniques that goal countless immune checkpoints and/or beautify T cell activation are probable wished to enhance manage of cervical cancer. Additionally, the therapeutic advantages of combining ICIs, radiotherapy, and chemotherapy for the remedy of cervical cancers are additionally beneath investigation (154) in quite a few clinical trials are evaluating such tri-modal cure (NCT03192059, NCT02635360). In addition, immune checkpoint inhibitors in mixture with radiation remedy have been explored in patients with cervical cancer, and the aggregate of techniques do now not end result in extended toxicity (154,224).

III. Future Directions

In the United States, cervical cancers is one of only two cancers for which survival has no longer appreciably accelerated given that the Seventies (5). For people recognized with metastatic, recurrent, or persistent cervical cancer, five-year survival is < 20%, and there are few cure choices (225,226). Therefore, there is a clear need for extended cervical cancers therapeutics. With the growing understanding of techniques to generate cervical cancers antigen-specific T cells and methods to reverse immunosuppression and assist effector immune cells in the TME, we have chance to create better, safer remedies for the management of cervical cancer. Clearly there are many possibilities to enhance therapy by means of combining one-of-a-kind immunotherapeutic techniques in order to locate synergistic therapeutic effects. Furthermore, immunotherapy can additionally be used in conjunction with traditional standard-of-care treatments, such as chemoradiation, to enhance outcome. One of the principal boundaries for the manipulate of cervical cancers by way of immunotherapy is the transport of immune cells, antibodies and pills during the tumor micro-environment, thereby limiting efficacy. For example, CAR-T cells have been most advantageous in “liquid” hematological cancers and much less tremendous in solid tumors, the place their get admission to to the complete tumor might also be limited. Another instance is so referred to as “cold tumors”, which have low lymphocyte infiltration and immune activation. As a result, ICI remedy can also be much less positive in cold bloodless tumors than in tumors with some ongoing antitumor response and tumor-infiltrating immune cells (227,228).

Without local immune cells expressing the applicable markers, antibodies such as anti-PD-L1 can't considerably assist clear tumors. Therefore, future research to tackle this confined get entry to key immune cells, antibodies and drugs to the tumor micro-environment can probably lead to higher manipulate of cervical cancer. HPV infection is a primary etiological component in the improvement of cervical cancers and is current in 95% of cases (1,15). Because of this, immunotherapeutic selections have a clear goal antigen that is ubiquitous in infected cells, foreign, and absent from healthy tissue (229). This simplifies antigen-specific immunotherapeutic improvement for cervical cancers relative to most different cancers, which have no well-defined, persistently expressed antigens. Cervical intraepithelial neoplasia is the instantaneous precursor of cervical cancer. Current general of care surgical cure prevents the majority of CIN2/3 from progressing to cervical cancer; however, there are possible reproductive ramifications and drawbacks (230,231). Most therapeutic HPV vaccines goal both high-grade intraepithelial lesions and/or cervical cancer. However, persistent high-risk HPV infection precedes the improvement of high-grade lesions and cancer, and presently there is no clinical remedy to do away with continual HPV infection. Few vaccines in development focus of attention on the removal of high risk persistent HPV infection, even though there is presently a phase II clinical trial underway for the manage of chronic HPV16 infection (NCT03911076). If a remedy for continual HPV infection is developed, it would restriction development of HPV infection to high grade lesions and cervical cancer. Future improvement of immunotherapy that ought to higher clear persistent high-risk HPV infections and stop development to cervical cancers stays of vast interest. Although there are many clinical trials and preclinical investigations concerning the use of immunotherapy for the manipulate of cervical cancer, so a long way solely pembrolizumab has been authorized for clinical use for persistent cervical cancer. With the FDA

approval of pembrolizumab for the remedy of metastatic/recurrent cervical cancer, we anticipate there will be different comparable immunotherapeutic processes concentrated on distinct factors of the immune enviroment that can enhance manage of cervical cancer. We are hopeful for the future of cervical cancers immunotherapy given the breadth of novel treatment beneath improvement that focus attention on the era of HPV antigen specific T cells and the modulation of tumor micro-environment to enhance typical disease manage and results for cervical cancers patients with generally tolerable side effects.

IV. Abbreviations

HPV: Human PapillomaVirus

hrHPV: high risk Human PapillomaVirus

HDI: Human Development Index

CIN 1/2/3: Cervical Intraepithelial Neoplasia 1/2/3

LSIL: Low-grade Squamous Intraepithelial Lesion

HSIL: High-grade Squamous Intraepithelial Lesion

ACT: Adoptive Cell Therapy TIL Tumor Infiltrating Lymphocytes

TME: Tumor Micro-environment

LLO: ListerioLysin O VIN Vulvar Intraepithelial Neoplasia

VAIN: Vaginal Intraepithelial Neoplasia

MVA: Modified Vaccinia virus Ankara

DC: Dendritic Cell

MDSC: Myeloid-Derived Suppressor Cell

IDO: Indoleamine Dioxygen OS Overall Survival

APC: Antigen Presenting Cell HLA Human Leukocyte Antigen

ASC-US: Atypical Squamous Cells of Undetermined Significance

ASC-H: Atypical Squamous Cells, cannot exclude High-Grade

UCPVax: Universal Cancer Peptide Vaccine

HSP70: Heat Shock Protein 70

TA-CIN: Tissue Antigen-Cervical Intraepithelial Neoplasia vaccine

TCR: engineered T-Cell Receptor T cells

CAR: Chimeric Antigen Receptor

CTLA-4: Cytotoxic T-Lymphocyte associated Antigen 4

PD-1: Programmed cell Death receptor

PD-L1: Programmed cell Death receptor Ligand

ICI: Immune Checkpoint Inhibitor

irAE: immune related Adverse Event

GITR: Glucocorticoid-Induced TNFR-Regulated protein

TAM: Tumor Associated Macrophages

V. Conflict of Interest

All authors declare no conflicts of interest.

VI. Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]-Yu, Pian, et al. "Pyroptosis: mechanisms and diseases." Signal transduction and targeted therapy 6.1 (2021): 128.

[2]-Ferrall, Louise, et al. "Cervical cancer immunotherapy: facts and hopes." Clinical Cancer Research 27.18 (2021): 4953-4973.

[3]-Singh, Deependra, et al. "Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative." The Lancet Global Health 11.2 (2023): e197-e206.

[4]-Kombe Kombe, Arnaud John, et al. "Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation." Frontiers in public health 8 (2021): 552028.

[5]-Miller, Kimberly D., et al. "Updated methodology for projecting US-and state-level cancer counts for the current calendar year: part II: evaluation of incidence and mortality projection methods." Cancer Epidemiology, Biomarkers & Prevention 30.11 (2021): 1993-2000.

[6]-Ferrall, Louise, et al. "Cervical cancer immunotherapy: facts and hopes." Clinical Cancer Research 27.18 (2021): 4953-4973.

[7]-O'Malley, David M., et al. "Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study." Journal of clinical oncology 40.7 (2022): 762.

[8]-Najafi, Sajad, et al. "Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis." Experimental Cell Research (2022): 113294.

[9]-Najafi, Sajad, et al. "Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis." Experimental Cell Research (2022): 113294.

[10]-Colombo, Nicoletta, et al. "Pembrolizumab for persistent, recurrent, or metastatic cervical cancer." New England Journal of Medicine 385.20 (2021): 1856-1867.

[11]-Bhatla, Neerja, et al. "Cancer of the cervix uteri: 2021 update." International Journal of Gynecology & Obstetrics 155 (2021): 28-44.

[12]-Mayadev, Jyoti S., et al. "Global challenges of radiotherapy for the treatment of locally advanced cervical cancer." International Journal of Gynecologic Cancer 32.3 (2022).

[13]-D'Oria, Ottavia, et al. "New advances in cervical cancer: from bench to bedside." International Journal of Environmental Research and Public Health 19.12 (2022): 7094.

[14]-Monk, Bradley J., et al. "Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials." Cancer treatment reviews 106 (2022): 102385.

[15]-Schmid, Maximilian P., et al. "Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study." Journal of Clinical Oncology 41.10 (2023): 1933-1942.

[16]-Monk, Bradley J., et al. "Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials." Cancer treatment reviews 106 (2022): 102385.

[17]-Horeweg, Nanda, et al. "A systematic review and meta-analysis of adjuvant chemotherapy after chemoradiation for locally advanced cervical cancer." Critical Reviews in Oncology/Hematology 172 (2022): 103638.

[18]-Sung, Hyuna, et al. "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." CA: a cancer journal for clinicians 71.3 (2021): 209-249.

[19]-Bhat, Ajaz A., et al. "Tumor micro-environment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy." Signal transduction and targeted therapy 6.1 (2021): 12.

[20]-Alemohammad, Hajar, et al. "The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer." Biomedicine & Pharmacotherapy 146 (2022): 112516.

[21]-Hu, Haoran, et al. "A pyroptosis-related gene panel for predicting the prognosis and immune micro-environment of cervical cancer." Frontiers in Oncology 12 (2022): 873725.

[22]-Kousar, Kousain, et al. "Immune landscape and immunotherapy options in cervical carcinoma." Cancers 14.18 (2022): 4458.

[23]-Sherer, Michael Vincent, et al. "Advances in immunotherapy for cervical cancer: recent developments and future directions." International Journal of Gynecologic Cancer 32.3 (2022).

[24]-Chakravarthy, Ankur, et al. "Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance." Nature communications 13.1 (2022): 5818.

[25]-Fu, Zhiwen, et al. "Antibody drug conjugate: the “biological missile” for targeted cancer therapy." Signal transduction and targeted therapy 7.1 (2022): 93.

[26]-Abiko, Kaoru, et al. "Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”." British Journal of Cancer 128.3 (2023): 461-467.

[27]-Colciago, Riccardo Ray, et al. "Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement." Expert Review of Anticancer Therapy 23.2 (2023): 135-145.

[28]-D’Oria, Ottavia, et al. "New advances in cervical cancer: from bench to bedside." International Journal of Environmental Research and Public Health 19.12 (2022): 7094.

[29]-Sharma, Padmanee, et al. "Immune checkpoint therapy—current perspectives and future directions." Cell 186.8 (2023): 1652-1669.

[30]-Małkiewicz, Bartosz, et al. "Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+)." Cancers 14.21 (2022): 5286.

[31]-De Jaeghere, Emiel A., et al. "Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study." Cancer Immunology, Immunotherapy 72.2 (2023): 475-491.

[32]-Pang, Xinghua, et al. "Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity." MAbs. Vol. 15. No. 1. Taylor & Francis, 2023.

[33]-Pulanco, Marc C., et al. "Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies." Cellular & Molecular Immunology (2023): 1-20.

[34]-Bhatla, Neerja, et al. "Adjuvant treatment in cervical, vaginal and vulvar cancer." Best Practice & Research Clinical Obstetrics & Gynaecology 78 (2022): 36-51.

[35]-Board, PDQ Adult Treatment Editorial. "Cervical Cancer Treatment (PDQ®): Health Professional Version." PDQ cancer information summaries [internet] (2002).

[36]-Manning-Geist, Beryl, et al. "Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation." International Journal of Gynecologic Cancer 32.12 (2022).

[37]-Petignat, Patrick, and Michel Roy. "Diagnosis and management of cervical cancer." Bmj 335.7623 (2007): 765-768.

[38]-Šarenac, Tanja, and Momir Mikov. "Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease." Frontiers in Pharmacology 10 (2019): 484.

[39]-Mackay, Helen J., Lari Wenzel, and Linda Mileshkin. "Non-surgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond." American Society of Clinical Oncology Educational Book 35.1 (2015): e299-e309.

[40]-Serkies, Krystyna, and Jacek Jassem. "Systemic therapy for cervical carcinoma–current status." Chinese Journal of Cancer Research 30.2 (2018): 209.

[41]-Burd, Eileen M. "Human papillomavirus and cervical cancer." Clinical microbiology reviews 16.1 (2003): 1-17.

[42]-Egawa, Nagayasu, et al. "Human papillomaviruses; epithelial tropisms, and the development of neoplasia." Viruses 7.7 (2015): 3863-3890.

[43]-Brianti, Pina, Eduardo De Flammineis, and Santo Raffaele Mercuri. "Review of HPV-related diseases and cancers." New Microbiol 40.2 (2017): 80-85.

[44]-Bansal, Anshuma, Mini P. Singh, and Bhavana Rai. "Human papillomavirus-associated cancers: A growing global problem." International Journal of Applied and Basic Medical Research 6.2 (2016): 84.

[45]-Doorbar, John, et al. "Human papillomavirus molecular biology and disease association." Reviews in medical virology 25 (2015): 2-23.

[46]-Ibeanu, Okechukwu A. "Molecular pathogenesis of cervical cancer." Cancer biology & therapy 11.3 (2011): 295-306.

[47]-Sanclemente, G., and D. K. Gill. "Human papillomavirus molecular biology and pathogenesis." Journal of the European Academy of Dermatology and Venereology 16.3 (2002): 231-240.

[48]-Ljubojevic, Suzana, and Mihael Skerlev. "HPV-associated diseases." Clinics in dermatology 32.2 (2014): 227-234.

[49]-Arbyn, Marc, et al. "EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease." International journal of cancer 131.9 (2012): 1969-1982.

[50]-Graham, Sheila V. "Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies." Future microbiology 5.10 (2010): 1493-1506.

[51]-Kash, Natalie, et al. "Safety and efficacy data on vaccines and immunization to human papillomavirus." Journal of clinical medicine 4.4 (2015): 614-633.

[52]-Joura, Elmar A., et al. "A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women." New England Journal of Medicine 372.8 (2015): 711-723.

[53]-Cuzick, Jack. "Gardasil 9 joins the fight against cervix cancer." Expert review of vaccines 14.8 (2015): 1047-1049.

[54]-Schiller, John T., and Martin Müller. "Next generation prophylactic human papillomavirus vaccines." The Lancet Oncology 16.5 (2015): e217-e225.

[55]-Signorelli, Carlo, et al. "Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence." Epidemiology & Infection 145.10 (2017): 1962-1982.

[56]-Ma, Barbara, et al. "Emerging human papillomavirus vaccines." Expert opinion on emerging drugs 17.4 (2012): 469-492.

[57]-Harper, Diane M., and Karen B. Williams. "Prophylactic HPV vaccines: current knowledge of impact on gynecologic pre malignancies." Discovery Medicine 10.50 (2010): 7-17.

[58]-Yang, Andrew, et al. "Current state in the development of candidate therapeutic HPV vaccines." Expert review of vaccines 15.8 (2016): 989-1007.

[59]-Cheng, Liqin, Yan Wang, and Juan Du. "Human papillomavirus vaccines: an updated review." Vaccines 8.3 (2020): 391.

[60]-Lott, Breanne E., et al. "Interventions to increase uptake of human papillomavirus (HPV) vaccination in minority populations: a systematic review." Preventive Medicine Reports 19 (2020): 101163.

[61]-Holman, Dawn M., et al. "Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature." JAMA pediatrics 168.1 (2014): 76-82.

[62]-Khan, Mina S., and Margot Savoy. "Impact of human papillomavirus vaccination in reducing cancer." Primary Care: Clinics in Office Practice 47.3 (2020): 529-537.

[63]-Khan, Mina S., and Margot Savoy. "Impact of human papillomavirus vaccination in reducing cancer." Primary Care: Clinics in Office Practice 47.3 (2020): 529-537.

[64]-Lin, Ken, et al. "Therapeutic HPV DNA vaccines." Immunologic research 47 (2010): 86-112.

[65]-Klaes, Ruediger, et al. "Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes." Cancer research 59.24 (1999): 6132-6136.

[66]-Vici, P., et al. "Targeting immune response with therapeutic vaccines in pre malignant lesions and cervical cancer: hope or reality from clinical studies." Expert review of vaccines 15.10 (2016): 1327-1336.

[67]-Van Der Burg, Sjoerd H., and Cornelis JM Melief. "Therapeutic vaccination against human papilloma virus induced malignancies." Current opinion in immunology 23.2 (2011): 252-257.

[68]-Melief, Cornelis JM, and Sjoerd H. Van Der Burg. "Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines." Nature Reviews Cancer 8.5 (2008): 351-360.

[69]-Hung, Chien-Fu, et al. "DNA vaccines for cervical cancer: from bench to bedside." Experimental & molecular medicine 39.6 (2007): 679-689.

[70]-Rosenberg, Steven A., and Nicholas P. Restifo. "Adoptive cell transfer as personalized immunotherapy for human cancer." Science 348.6230 (2015): 62-68.

[71]-Bianchi, Valentina, Alexandre Harari, and George Coukos. "Neoantigen-specific adoptive cell therapies for cancer: making T-cell products more personal." Frontiers in immunology 11 (2020): 1215.

[72]-Zsiros, Emese, Takemasa Tsuji, and Kunle Odunsi. "Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer." Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 33.14 (2015): 1521-1522.

[73]-Stevanović, Sanja, et al. "Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer." Science 356.6334 (2017): 200-205.

[74]-Mortezaee, Keywan. "Immune escape: A critical hallmark in solid tumors." Life sciences 258 (2020): 118110.

[75]-Pardoll, Drew M. "The blockade of immune checkpoints in cancer immunotherapy." Nature reviews cancer 12.4 (2012): 252-264.

[76]-Strosberg, Jonathan, et al. "Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study." Clinical cancer research 26.9 (2020): 2124-2130.

[77]-Sewell, Duane A., Zhen Kun Pan, and Yvonne Paterson. "Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors." Vaccine 26.41 (2008): 5315-5320.

[78]-Bermudez-Humaran, Luis G., et al. "An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci." Journal of medical microbiology 53.5 (2004): 427-433.

[79]-Cortes-Perez, Naima G., et al. "Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli." Journal of drug targeting 13.2 (2005): 89-98.

[80]-Adachi, Katsuyuki, et al. "Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7." Vaccine 28.16 (2010): 2810-2817.

[81]-Schnupf, Pamela, and Daniel A. Portnoy. "Listeriolysin O: a phagosome-specific lysin." Microbes and infection 9.10 (2007): 1176-1187.

[82]-Peters, Christian, and Yvonne Paterson. "Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts." Vaccine 21.11-12 (2003): 1187-1194.

[83]-Chen, Zhisong, et al. "Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+ FoxP3− and CD8+ T Cells." Cancer immunology research 2.9 (2014): 911-922.

[84]-Huh, Warner K., et al. "Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study." Gynecologic oncology 158.3 (2020): 562-569.

[85]-Gomez-Gutierrez, Jorge G., et al. "Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice." Cancer Immunology, Immunotherapy 56 (2007): 997-1007.

[86]-Liu, Dai-Wei, et al. "Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer." Journal of virology 74.6 (2000): 2888-2894.

[87]-Cassetti, M. Cristina, et al. "Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes." Vaccine 22.3-4 (2004): 520-527.

[88]-Hsieh, Chia-Jung, et al. "Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin." Vaccine 22.29-30 (2004): 3993-4001.

[89]-Borysiewicz, L. K., et al. "A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer." The Lancet 347.9014 (1996): 1523-1527.

[90]-Lamikanra, Abigail, et al. "Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site." Journal of virology 75.20 (2001): 9654-9664.

[91]-Baldwin, Peter J., et al. "Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia." Clinical Cancer Research 9.14 (2003): 5205-5213.

[92]-Harper, Diane M., et al. "The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up." Gynecologic oncology 153.3 (2019): 521-529.

[93]-Yang, Andrew, et al. "The current state of therapeutic and T cell-based vaccines against human papillomaviruses." Virus research 231 (2017): 148-165.

[94]-Komdeur, Fenne L., et al. "First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers." Molecular therapy 29.2 (2021): 611-625.

[95]-Ginaldi, Lia, et al. "Immunosenescence and infectious diseases." Microbes and Infection 3.10 (2001): 851-857.

[96]-Lee, Sung-Jong, et al. "Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research." Journal of gynecologic oncology 27.5 (2016).

[97]-Mackova, Jana, et al. "Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12." International journal of oncology 24.6 (2004): 1581-1588.

[98]-Wang, T. L., et al. "Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity." Gene therapy 7.9 (2000): 726-733.

[99]-Benencia, Fabian, Maria C. Courrèges, and George Coukos. "Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells." Journal of translational medicine 6.1 (2008): 1-14.

[100]-Murakami, Masaru, et al. "Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells." Cancer research 59.6 (1999): 1184-1187.

[101]-Peng, Shiwen, et al. "Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life." Human gene therapy 16.5 (2005): 584-593.

[102]-Kim, Jin Hee, et al. "Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8+ T cell-mediated cell death." Immunology letters 122.1 (2009): 58-67.

[103]-Adams, M., et al. "Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C12U](Ampligen®)." Vaccine 21.7-8 (2003): 787-790.

[104]-Santin, Alessandro D., et al. "Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy." Current pharmaceutical design 11.27 (2005): 3485-3500.

[105]-Santin, Alessandro D., et al. "Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial." Journal of virology 82.4 (2008): 1968-1979.

[106]-Ramanathan, Priya, et al. "Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study." Asian Pacific Journal of Cancer Prevention 15.14 (2014): 5909-5916.

[107]-Kenter, Gemma G., et al. "Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity." Clinical cancer research 14.1 (2008): 169-177.

[108]-Kenter, Gemma G., et al. "Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia." New England Journal of Medicine 361.19 (2009): 1838-1847.

[109]-van Poelgeest, Mariëtte IE, et al. "Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response." Clinical Cancer Research 22.10 (2016): 2342-2350.

[110]-Van der Burg, S. H., et al. "Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens." Vaccine 19.27 (2001): 3652-3660.

[111]-De Jong, A., et al. "Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine." Vaccine 20.29-30 (2002): 3456-3464.

[112]-Davidson, Emma J., et al. "Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)." Vaccine 22.21-22 (2004): 2722-2729.

[113]-Smyth, Lucy JC, et al. "Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination." Clinical Cancer Research 10.9 (2004): 2954-2961.

[114]-Daayana, Sai, et al. "Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia." British journal of cancer 102.7 (2010): 1129-1136.

[115]-Da Silva, Diane M., et al. "Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease." Vaccine 37.22 (2019): 2915-2924.

[116]-Dosset, Magalie, et al. "Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination." Oncoimmunology 2.3 (2013): e23430.

[117]-Galaine, Jeanne, et al. "Heparan sulfate proteoglycans promote telomerase internalization and MHC class II presentation on dendritic cells." The Journal of Immunology 197.5 (2016): 1597-1608.

[118]-Dosset, Magalie, et al. "Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor." Clinical Cancer Research 18.22 (2012): 6284-6295.

[119]-Kim, J. W., et al. "Comparison of HPV DNA vaccines employing intracellular targeting strategies." Gene therapy 11.12 (2004): 1011-1018.

[120]-Choi, Youn Jin, et al. "A phase II, prospective, randomized, multicentre, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3." Clinical Cancer Research 26.7 (2020): 1616-1623.

[121]-Kim, Tae Jin, et al. "Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients." Nature communications 5.1 (2014): 5317.

[122]-Trimble, Cornelia L., et al. "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial." The Lancet 386.10008 (2015): 2078-2088.

[123]-Bagarazzi, Mark L., et al. "Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses." Science translational medicine 4.155 (2012): 155ra138-155ra138.

[124]-INOVIO Pharmaceuticals, Inc. "INOVIO announces positive results from REVEAL 1, a phase 3 pivotal trial evaluating VGX-3100, its DNA-based HPV immunotherapy for the treatment of high-grade precancerous cervical dysplasia caused by HPV-16 and/or HPV-18." (2021): 1-6.

[125]-Hasan, Yasmin, et al. "A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer." International Journal of Radiation Oncology* Biology* Physics 107.3 (2020): 487-498.

[126]-Aggarwal, Charu, et al. "Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer." Clinical Cancer Research 25.1 (2019): 110-124.

[127]-Trimble, Cornelia L., et al. "A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3." Clinical Cancer Research 15.1 (2009): 361-367.

[128]-Alvarez, Ronald D., et al. "A pilot study of pNGVL4a-CRT/E7 (detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)." Gynecologic oncology 140.2 (2016): 245-252.

[129]-Kim, Daejin, et al. "Generation and characterization of a preventive and therapeutic HPV DNA vaccine." Vaccine 26.3 (2008): 351-360.

[130]-Schild, Hansjörg, et al. "Cutting Edge: Receptor-Mediated." J Immunol 162 (1999): 3757-3760.

[131]-Hillemanns, Peter, et al. "Abstract CT209: Safety, efficacy and immunogenicity of VB10. 16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial." Cancer Research 79.13_Supplement (2019): CT209-CT209.

[132]-Sahin, Ugur, et al. "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses." Nature 586.7830 (2020): 594-599.

[133]-Grunwitz, Christian, et al. "HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory." Oncoimmunology 8.9 (2019): e1629259.

[134]-Cheng, Wen-Fang, et al. "Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22–antigen fusion." Human gene therapy 13.4 (2002): 553-568.

[135]-BERGLUND, PETER, et al. "Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus." AIDS research and human retroviruses 13.17 (1997): 1487-1495.

[136]-Hung, Chien-Fu, et al. "Therapeutic human papillomavirus vaccines: current clinical trials and future directions." Expert opinion on biological therapy 8.4 (2008): 421-439.

[137]-Hsu, Keng-Fu, et al. "Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen." Gene therapy 8.5 (2001): 376-383.

[138]-Cheng, Wen-Fang, et al. "Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments." Human gene therapy 12.3 (2001): 235-252.

[139]-van de Wall, Stephanie, et al. "Potent therapeutic efficacy of an alpha virus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens." Oncoimmunology 7.10 (2018): e1487913.

[140]-Kim, T. W., et al. "Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death." Gene therapy 11.3 (2004): 336-342.

[141]-Kim, Tae Woo, et al. "Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency." Cancer research 65.1 (2005): 309-316.

[142]-Peng, Shiwen, et al. "Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease." Cell & bioscience 6 (2016): 1-14.

[143]-Rohaan, Maartje W., Sofie Wilgenhof, and John BAG Haanen. "Adoptive cellular therapies: the current landscape." Virchows Archiv 474 (2019): 449-461.

[144]-Sukari, Ammar, Nadine Abdallah, and Misako Nagasaka. "Unleash the power of the mighty T cells-basis of adoptive cellular therapy." Critical Reviews in Oncology/Hematology 136 (2019): 1-12.

[145]-Draper, Lindsey M., et al. "Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6." Clinical Cancer Research 21.19 (2015): 4431-4439.

[146]-Mantovani, Alberto, et al. "Tumor-associated myeloid cells: diversity and therapeutic targeting." Cellular & molecular immunology 18.3 (2021): 566-578.

[147]-Stevanović, Sanja, et al. "Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells." Journal of Clinical Oncology 33.14 (2015): 1543.

[148]-Jeanbart, Laura, and Melody A. Swartz. "Engineering opportunities in cancer immunotherapy." Proceedings of the National Academy of Sciences 112.47 (2015): 14467-14472.

[149]-Hossain, Nasheed M., Aude G. Chapuis, and Roland B. Walter. "T-Cell Receptor-Engineered cells for the treatment of hematologic malignancies." Current hematologic malignancy reports 11 (2016): 311-317.

[150]-Kelderman, Sander, et al. "Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy." European journal of immunology 46.6 (2016): 1351-1360.

[151]-Schober, Kilian, and Dirk H. Busch. "TIL 2.0: More effective and predictive T-cell products by enrichment for defined antigen specificities." European Journal of Immunology 46.6 (2016): 1335-1339.

[152]-Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo. "Prospects for gene-engineered T cell immunotherapy for solid cancers." Nature medicine 22.1 (2016): 26-36.

[153]-van Poelgeest, Mariëtte IE, et al. "Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer." Cancer Immunology, Immunotherapy 65 (2016): 1451-1463.

[154]-Li, Ning, et al. "Combined treatment with autologous CIK cells, radiotherapy and chemotherapy in advanced cervical cancer." Pathology & Oncology Research 25.2 (2019): 691-696.

[155]-Doran, Stacey L., et al. "Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial." (2018): 3019-3019.

[156]-Dai, Hanren, et al. "Chimeric antigen receptors modified T-cells for cancer therapy." Journal of the National Cancer Institute 108.7 (2016): djv439.

[157]-Haji-Fatahaliha, Mostafa, et al. "CAR-modified T-cell therapy for cancer: an updated review." Artificial cells, nanomedicine, and biotechnology 44.6 (2016): 1339-1349.

[158]-Zhang, Hao, et al. "New strategies for the treatment of solid tumors with CAR-T cells." International journal of biological sciences 12.6 (2016): 718.

[159]-Callahan, Margaret K., Catherine R. Flaherty, and Michael A. Postow. "Checkpoint blockade for the treatment of advanced melanoma." Melanoma (2016): 231-250.

[160]-Lyford-Pike, Sofia, et al. "Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma." Cancer research 73.6 (2013): 1733-1741.

[161]-Allouch, Soumaya, et al. "High-risk HPV oncoproteins and PD-1/PD-L1 interplay in human cervical cancer: recent evidence and future directions." Frontiers in Oncology 10 (2020): 914.

[162]-Mezache, Louisa, et al. "Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers." Modern Pathology 28.12 (2015): 1594-1602.

[163]-Borcoman, Edith, and Christophe Le Tourneau. "Pembrolizumab in cervical cancer: latest evidence and clinical usefulness." Therapeutic advances in medical oncology 9.6 (2017): 431-439.

[164]-Lyu, Mengmeng, et al. "The combined use of chemotherapy and radiotherapy with PD-1 inhibitor, pembrolizumab, in advanced cervical cancer: a case report." OncoTargets and therapy (2020): 4465-4471.

[165]-Liang, Yun, et al. "Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy." Diagnostic Pathology 15 (2020): 1-8.

[166]-Hollebecque, Antoine, et al. "An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers." (2017): 5504-5504.

[167]-Frenel, Jean-Sebastien, et al. "Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study." (2016): 5515-5515.

[168]-Van Coillie, Samya, Bartosz Wiernicki, and Jie Xu. "Molecular and cellular functions of CTLA-4." Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy (2020): 7-32.

[169]-Hodi, F. Stephen, et al. "Improved survival with ipilimumab in patients with metastatic melanoma." New England Journal of Medicine 363.8 (2010): 711-723.

[170]-Hosseini, Arezoo, et al. "CTLA-4: From mechanism to autoimmune therapy." International immunopharmacology 80 (2020): 106221.

[171]-Egen, Jackson G., Michael S. Kuhns, and James P. Allison. "CTLA-4: new insights into its biological function and use in tumor immunotherapy." Nature immunology 3.7 (2002): 611-618.

[172]-Lheureux, Stephanie, et al. "A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia." (2015): 3061-3061.

[173]-Guo, Liting, Haijun Zhang, and Baoan Chen. "Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor." Journal of Cancer 8.3 (2017): 410.

[174]-Zhong, Hui, et al. "Rheumatic immune-related adverse events induced by immune checkpoint inhibitors." Asia-Pacific Journal of Clinical Oncology 17.3 (2021): 178-185.

[175]-Aspeslagh, Sandrine, et al. "Rationale for anti-OX40 cancer immunotherapy." European Journal of Cancer 52 (2016): 50-66.

[176]-Shrimali, Rajeev K., et al. "Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis." Cancer immunology research 5.9 (2017): 755-766.

[177]-Glisson, Bonnie S., et al. "Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors." Clinical Cancer Research 26.20 (2020): 5358-5367.

[178]-Padovani, Cacilda Tezelli Junqueira, et al. "Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection." Revista da Sociedade Brasileira de Medicina Tropical 46 (2013): 288-292.

[179]-Knee, Deborah A., Becker Hewes, and Jennifer L. Brogdon. "Rationale for anti-GITR cancer immunotherapy." European journal of cancer 67 (2016): 1-10.

[180]-Andrews, Lawrence P., et al. "LAG 3 (CD 223) as a cancer immunotherapy target." Immunological reviews 276.1 (2017): 80-96.

[181]-Panda, Anshuman, et al. "Genomic and immunologic correlates of LAG-3 expression in cancer." Oncoimmunology 9.1 (2020): 1756116.

[182]-Cao, Yang, et al. "Tim-3 expression in cervical cancer promotes tumor metastasis." PloS one 8.1 (2013): e53834.

[183]-Solinas, Cinzia, et al. "Significance of TIM3 expression in cancer: From biology to the clinic." Seminars in oncology. Vol. 46. No. 4-5. WB Saunders, 2019.

[184]-de Lourdes Mora-García, María, et al. "HPV-16 infection is associated with a high content of CD39 and CD73 ectonucleotidases in cervical samples from patients with CIN-1." Mediators of inflammation 2019 (2019).

[185]-Gutiérrez-Hoya, Adriana, et al. "Cervical cancer cells express markers associated with immunosurveillance." Journal of immunology research 2019 (2019).

[186]-Moesta, Achim K., Xian-Yang Li, and Mark J. Smyth. "Targeting CD39 in cancer." Nature Reviews Immunology 20.12 (2020): 739-755.

[187]-Simoni, Yannick, et al. "Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates." Nature 557.7706 (2018): 575-579.

[188]-Duhen, Thomas, et al. "Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors." Nature communications 9.1 (2018): 2724.

[189]-Kortekaas, Kim E., et al. "CD39 identifies the CD4+ tumor-specific T-cell population in human cancer." Cancer immunology research 8.10 (2020): 1311-1321.

[190]-García-Rocha, Rosario, et al. "Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1." Cytokine 118 (2019): 71-79.

[191]-Leone, Robert D., Ying-Chun Lo, and Jonathan D. Powell. "A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy." Computational and structural biotechnology journal 13 (2015): 265-272.

[192]-O'Donnell, Jake S., Michele WL Teng, and Mark J. Smyth. "Cancer immunoediting and resistance to T cell-based immunotherapy." Nature reviews Clinical oncology 16.3 (2019): 151-167.

[193]-Glodde, Nicole, et al. "Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy." Immunity 47.4 (2017): 789-802.

[194]-De Henau, Olivier, et al. "Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells." Nature 539.7629 (2016): 443-447.

[195]-Boromand, Nadia, et al. "Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer." Journal of Cellular Physiology 233.6 (2018): 4490-4496.

[196]-Walch-Rückheim, Barbara, et al. "Cervical cancer–instructed stromal fibroblasts enhance IL23 expression in dendritic cells to support expansion of Th17 cells." Cancer research 79.7 (2019): 1573-1586.

[197]-Lin, Wei, et al. "Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer." International journal of clinical and experimental pathology 12.9 (2019): 3604.

[198]-Zhang, Zun-Sheng, et al. "Oncogenic role of Tc17 cells in cervical cancer development." World Journal of Clinical Cases 8.1 (2020): 11.

[199]-Bahrami, Afsane, et al. "The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy." Journal of Cellular Biochemistry 118.12 (2017): 4163-4169.

[200]-Cao, Penglong, et al. "PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673." Oncology Reports 42.5 (2019): 2097-2107.

[201]-Li, Yong-Jie, Yue Wang, and Yi-Ying Wang. "Retracted: microRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway." (2019): 9577-9591.

[202]-Zhang, Wenyuan, et al. "The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer." International journal of clinical and experimental pathology 12.7 (2019): 2474.

[203]-Bossler, Felicitas, Karin Hoppe-Seyler, and Felix Hoppe-Seyler. "PI3K/AKT/mTOR signaling regulates the virus/host cell crosstalk in HPV-positive cervical cancer cells." International journal of molecular sciences 20.9 (2019): 2188.

[204]-Bedoya, Astrid M., et al. "Immunosuppression in cervical cancer with special reference to arginase activity." Gynecologic Oncology 135.1 (2014): 74-80.

[205]-Steggerda, Susanne M., et al. "Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor micro-environment." Journal for immunotherapy of cancer 5.1 (2017): 1-18.

[206]-Cheong, Jae Eun, and Lijun Sun. "Targeting the IDO1/TDO2–KYN–AhR pathway for cancer immunotherapy–challenges and opportunities." Trends in pharmacological sciences 39.3 (2018): 307-325.

[207]-Sato, Naoto, et al. "Downregulation of indoleamine-2, 3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation." Oncology reports 28.5 (2012): 1574-1578.

[208]-Chinn, Zachary, Mark H. Stoler, and Anne M. Mills. "PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy." Histopathology 74.2 (2019): 256-268.

[209]-Tewari, Krishnansu S., et al. "Improved survival with bevacizumab in advanced cervical cancer." New England Journal of Medicine 370.8 (2014): 734-743.

[210]-Minion, Lindsey E., and Krishnansu S. Tewari. "Cervical cancer–State of the science: From angiogenesis blockade to checkpoint inhibition." Gynecologic oncology 148.3 (2018): 609-621.

[211]-Shevtsov, Maxim, et al. "Novel approaches to improve the efficacy of immuno-radiotherapy." Frontiers in oncology 9 (2019): 156.

[212]-Van Meir, H., et al. "Impact of (chemo) radiotherapy on immune cell composition and function in cervical cancer patients." Oncoimmunology 6.2 (2017): e1267095.

[213]-Zhao, Jing, et al. "Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment." Frontiers in pharmacology 10 (2019): 1184.

[214]-Mougel, Alice, Magali Terme, and Corinne Tanchot. "Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade." Frontiers in immunology 10 (2019): 467.

[215]-Rice, Adrian E., et al. "An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression." Cancer gene therapy 22.9 (2015): 454-462.

[216]-Peng, Shiwen, et al. "Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody." MBio 12.1 (2021): 10-1128.

[217]-Massarelli, Erminia, et al. "Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial." JAMA oncology 5.1 (2019): 67-73.

[218]-Youn, Jin Won, et al. "Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial." The Lancet Oncology 21.12 (2020): 1653-1660.

[219]-Tseng, Chih-Wen, et al. "Pretreatment with cisplatin enhances E7-specific CD8+ T-cell–mediated antitumor immunity induced by DNA vaccination." Clinical cancer research 14.10 (2008): 3185-3192.

[220]-Melief, Cornelis JM, et al. "Strong vaccine responses during chemotherapy are associated with prolonged cancer survival." Science translational medicine 12.535 (2020): eaaz8235.

[221]-Beyranvand Nejad, Elham, et al. "Tumor eradication by cisplatin is sustained by CD80/86-mediated costimulation of CD8+ T cells." Cancer research 76.20 (2016): 6017-6029.

[222]-Lee, Sung Yong, et al. "Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects." Cancer Immunology, Immunotherapy 62 (2013): 1175-1185.

[223]-Basu, Partha, et al. "ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer." (2014): 5610-5610.

[224]-Congzhou, M. Sha, et al. "Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis." Radiotherapy and Oncology 151 (2020): 141-148.

[225]-Pfaendler, Krista S., and Krishnansu S. Tewari. "Changing paradigms in the systemic treatment of advanced cervical cancer." American journal of obstetrics and gynecology 214.1 (2016): 22-30.

[226]-Li, Haoran, Xiaohua Wu, and Xi Cheng. "Advances in diagnosis and treatment of metastatic cervical cancer." Journal of gynecologic oncology 27.4 (2016).

[227]-Binnewies, Mikhail, et al. "Understanding the tumor immune micro-environment (TIME) for effective therapy." Nature medicine 24.5 (2018): 541-550.

[228]-Li, Bailiang, et al. "The immune subtypes and landscape of squamous cell carcinoma." Clinical Cancer Research 25.12 (2019): 3528-3537.

[229]-Barra, Fabio, et al. "Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia." Journal of Obstetrics and Gynaecology Research 46.7 (2020): 989-1006.

[230]-Desravines, Nerlyne, et al. "Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: A narrative review." Gynecologic oncology reports 33 (2020): 100608.

[231]-Castle, Philip E., et al. "Treatment of cervical intraepithelial lesions." International Journal of Gynecology & Obstetrics 138 (2017): 20-25.